{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "machine_shape": "hm",
      "authorship_tag": "ABX9TyMXXEgUVjoLeswpJ9jXB5WK",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "ir",
      "display_name": "R"
    },
    "language_info": {
      "name": "R"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/julianflowers/spha/blob/main/Amr.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nZFjB9ipX9LZ",
        "outputId": "7c069449-2b73-4e32-95d0-126553d5570e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Installing package into ‘/usr/local/lib/R/site-library’\n",
            "(as ‘lib’ is unspecified)\n",
            "\n"
          ]
        }
      ],
      "source": [
        "install.packages('pak')\n",
        "library(pak)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pak(\"tidyverse\")\n",
        "pak::pkg_install(\"ropensci/fingertipsR\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hpojeV-MYpUa",
        "outputId": "2b9177c7-ac41-4c94-b01e-009a9273ffe0"
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\n",
            "\n",
            "\u001b[32m✔\u001b[39m Updated metadata database: 2.91 MB in 8 files.\n",
            "\n",
            "\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Updating metadata database\n",
            "\n",
            "\u001b[32m✔\u001b[39m Updating metadata database ... done\n",
            "\n",
            "\n",
            "\n",
            " \n",
            "\n",
            "→ Will \u001b[3m\u001b[3minstall\u001b[3m\u001b[23m 102 packages.\n",
            "\n",
            "→ Will \u001b[3m\u001b[3mdownload\u001b[3m\u001b[23m 102 CRAN packages (68.12 MB).\n",
            "\n",
            "\u001b[90m+ \u001b[39m\u001b[34maskpass\u001b[39m         1.2.0   [bld][cmp][dl] \u001b[90m(6.04 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbackports\u001b[39m       1.4.1   [bld][cmp][dl] \u001b[90m(26.20 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbase64enc\u001b[39m       0.1-3   [bld][cmp][dl] \u001b[90m(7.83 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbit\u001b[39m             4.0.5   [bld][cmp][dl] \u001b[90m(827.75 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbit64\u001b[39m           4.0.5   [bld][cmp][dl] \u001b[90m(135.09 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mblob\u001b[39m            1.2.4   [bld][dl] \u001b[90m(10.62 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbroom\u001b[39m           1.0.5   [bld][dl] \u001b[90m(641.85 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mbslib\u001b[39m           0.7.0   [bld][dl] \u001b[90m(5.13 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcachem\u001b[39m          1.0.8   [bld][cmp][dl] \u001b[90m(26.51 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcallr\u001b[39m           3.7.6   [bld][dl] \u001b[90m(104.36 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcellranger\u001b[39m      1.1.0   [bld][dl] \u001b[90m(63.86 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcli\u001b[39m             3.6.2   [bld][cmp][dl] \u001b[90m(569.77 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mclipr\u001b[39m           0.8.0   [bld][dl] \u001b[90m(21.90 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcolorspace\u001b[39m      2.1-0   [bld][cmp][dl] \u001b[90m(2.12 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mconflicted\u001b[39m      1.2.0   [bld][dl] \u001b[90m(17.07 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcpp11\u001b[39m           0.4.7   [bld][dl] \u001b[90m(285.78 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcrayon\u001b[39m          1.5.2   [bld][dl] \u001b[90m(40.57 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcurl\u001b[39m            5.2.1   [bld][cmp][dl] \u001b[90m(716.70 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libcurl4-openssl-dev\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m libssl-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mdata.table\u001b[39m      1.15.4  [bld][cmp][dl] \u001b[90m(5.39 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mDBI\u001b[39m             1.2.2   [bld][dl] \u001b[90m(1.13 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mdbplyr\u001b[39m          2.5.0   [bld][dl] \u001b[90m(770.65 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mdigest\u001b[39m          0.6.35  [bld][cmp][dl] \u001b[90m(230.39 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mdplyr\u001b[39m           1.1.4   [bld][cmp][dl] \u001b[90m(1.21 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mdtplyr\u001b[39m          1.3.1   [bld][dl] \u001b[90m(150.97 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mellipsis\u001b[39m        0.3.2   [bld][cmp][dl] \u001b[90m(8.07 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mevaluate\u001b[39m        0.23    [bld][dl] \u001b[90m(28.35 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfansi\u001b[39m           1.0.6   [bld][cmp][dl] \u001b[90m(482.48 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfarver\u001b[39m          2.1.1   [bld][cmp][dl] \u001b[90m(1.27 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfastmap\u001b[39m         1.1.1   [bld][cmp][dl] \u001b[90m(46.41 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfontawesome\u001b[39m     0.5.2   [bld][dl] \u001b[90m(1.28 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mforcats\u001b[39m         1.0.0   [bld][dl] \u001b[90m(294.18 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfs\u001b[39m              1.6.4   [bld][cmp][dl] \u001b[90m(1.19 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m make\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mgargle\u001b[39m          1.5.2   [bld][dl] \u001b[90m(627.56 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mgenerics\u001b[39m        0.1.3   [bld][dl] \u001b[90m(172.20 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mggplot2\u001b[39m         3.5.1   [bld][dl] \u001b[90m(3.56 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mglue\u001b[39m            1.7.0   [bld][cmp][dl] \u001b[90m(105.42 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mgoogledrive\u001b[39m     2.1.1   [bld][dl] \u001b[90m(1.61 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mgooglesheets4\u001b[39m   1.1.1   [bld][dl] \u001b[90m(232.58 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mgtable\u001b[39m          0.3.5   [bld][dl] \u001b[90m(130.10 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhaven\u001b[39m           2.5.4   [bld][cmp][dl] \u001b[90m(313.33 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m make\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m zlib1g-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhighr\u001b[39m           0.10    [bld][dl] \u001b[90m(15.08 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhms\u001b[39m             1.1.3   [bld][dl] \u001b[90m(43.38 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhtmltools\u001b[39m       0.5.8.1 [bld][cmp][dl] \u001b[90m(135.13 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhttr\u001b[39m            1.4.7   [bld][dl] \u001b[90m(118.50 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mids\u001b[39m             1.0.1   [bld][dl] \u001b[90m(91.21 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34misoband\u001b[39m         0.2.7   [bld][cmp][dl] \u001b[90m(1.59 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mjquerylib\u001b[39m       0.1.4   [bld][dl] \u001b[90m(520.21 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mjsonlite\u001b[39m        1.8.8   [bld][cmp][dl] \u001b[90m(1.05 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mknitr\u001b[39m           1.46    [bld][dl] \u001b[90m(471.55 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m pandoc\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mlabeling\u001b[39m        0.4.3   [bld][dl] \u001b[90m(10.17 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mlifecycle\u001b[39m       1.0.4   [bld][dl] \u001b[90m(107.66 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mlubridate\u001b[39m       1.9.3   [bld][cmp][dl] \u001b[90m(428.04 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mmagrittr\u001b[39m        2.0.3   [bld][cmp][dl] \u001b[90m(267.07 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mmemoise\u001b[39m         2.0.1   [bld][dl] \u001b[90m(17.85 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mmime\u001b[39m            0.12    [bld][cmp][dl] \u001b[90m(12.56 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mmodelr\u001b[39m          0.1.11  [bld][dl] \u001b[90m(121.48 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mmunsell\u001b[39m         0.5.1   [bld][dl] \u001b[90m(182.31 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mopenssl\u001b[39m         2.1.2   [bld][cmp][dl] \u001b[90m(1.21 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libssl-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mpillar\u001b[39m          1.9.0   [bld][dl] \u001b[90m(444.53 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mpkgconfig\u001b[39m       2.0.3   [bld][dl] \u001b[90m(6.08 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mprettyunits\u001b[39m     1.2.0   [bld][dl] \u001b[90m(97.50 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mprocessx\u001b[39m        3.8.4   [bld][cmp][dl] \u001b[90m(163.98 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mprogress\u001b[39m        1.2.3   [bld][dl] \u001b[90m(30.50 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mps\u001b[39m              1.7.6   [bld][cmp][dl] \u001b[90m(129.49 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mpurrr\u001b[39m           1.0.2   [bld][cmp][dl] \u001b[90m(220.87 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mR6\u001b[39m              2.5.1   [bld][dl] \u001b[90m(63.42 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mragg\u001b[39m            1.3.0   [bld][cmp][dl] \u001b[90m(430.24 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libfreetype6-dev\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m libjpeg-dev\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m libpng-dev\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m libtiff-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrappdirs\u001b[39m        0.3.3   [bld][cmp][dl] \u001b[90m(12.29 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mRColorBrewer\u001b[39m    1.1-3   [bld][dl] \u001b[90m(11.64 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mreadr\u001b[39m           2.1.5   [bld][cmp][dl] \u001b[90m(298.06 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mreadxl\u001b[39m          1.4.3   [bld][cmp][dl] \u001b[90m(2.09 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrematch\u001b[39m         2.0.0   [bld][dl] \u001b[90m(4.78 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrematch2\u001b[39m        2.1.2   [bld][dl] \u001b[90m(13.37 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mreprex\u001b[39m          2.1.0   [bld][dl] \u001b[90m(1.09 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m pandoc\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrlang\u001b[39m           1.1.3   [bld][cmp][dl] \u001b[90m(763.76 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrmarkdown\u001b[39m       2.26    [bld][dl] \u001b[90m(2.19 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m pandoc\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrstudioapi\u001b[39m      0.16.0  [bld][dl] \u001b[90m(117.42 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mrvest\u001b[39m           1.0.4   [bld][dl] \u001b[90m(115.88 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34msass\u001b[39m            0.4.9   [bld][cmp][dl] \u001b[90m(3.03 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m make\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mscales\u001b[39m          1.3.0   [bld][cmp][dl] \u001b[90m(302.54 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mselectr\u001b[39m         0.4-2   [bld][dl] \u001b[90m(41.37 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mstringi\u001b[39m         1.8.3   [bld][cmp][dl] \u001b[90m(11.92 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libicu-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mstringr\u001b[39m         1.5.1   [bld][dl] \u001b[90m(176.60 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34msys\u001b[39m             3.4.2   [bld][cmp][dl] \u001b[90m(20.17 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34msystemfonts\u001b[39m     1.0.6   [bld][cmp][dl] \u001b[90m(80.84 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libfontconfig1-dev\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m libfreetype6-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtextshaping\u001b[39m     0.3.7   [bld][cmp][dl] \u001b[90m(35.10 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libfreetype6-dev\u001b[39m, \u001b[36m\u001b[31m✖\u001b[36m libfribidi-dev\u001b[39m, \u001b[36m\u001b[31m✖\u001b[36m libharfbuzz-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtibble\u001b[39m          3.2.1   [bld][cmp][dl] \u001b[90m(565.98 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtidyr\u001b[39m           1.3.1   [bld][cmp][dl] \u001b[90m(809.06 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtidyselect\u001b[39m      1.2.1   [bld][cmp][dl] \u001b[90m(103.59 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtidyverse\u001b[39m       2.0.0   [bld][dl] \u001b[90m(704.62 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtimechange\u001b[39m      0.3.0   [bld][cmp][dl] \u001b[90m(103.44 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtinytex\u001b[39m         0.50    [bld][dl] \u001b[90m(34.31 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mtzdb\u001b[39m            0.4.0   [bld][cmp][dl] \u001b[90m(586.33 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mutf8\u001b[39m            1.2.4   [bld][cmp][dl] \u001b[90m(241.08 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34muuid\u001b[39m            1.2-0   [bld][cmp][dl] \u001b[90m(79.72 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mvctrs\u001b[39m           0.6.5   [bld][cmp][dl] \u001b[90m(969.07 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mviridisLite\u001b[39m     0.4.2   [bld][dl] \u001b[90m(1.27 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mvroom\u001b[39m           1.6.5   [bld][cmp][dl] \u001b[90m(750.42 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mwithr\u001b[39m           3.0.0   [bld][dl] \u001b[90m(107.68 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mxfun\u001b[39m            0.43    [bld][cmp][dl] \u001b[90m(144.50 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mxml2\u001b[39m            1.3.6   [bld][cmp][dl] \u001b[90m(294.71 kB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m libxml2-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34myaml\u001b[39m            2.3.8   [bld][cmp][dl] \u001b[90m(94.76 kB)\u001b[39m\n",
            "\n",
            "→ Will \u001b[3m\u001b[3minstall\u001b[3m\u001b[23m 2 system packages:\n",
            "\n",
            "\u001b[90m+ \u001b[39m\u001b[36mlibfribidi-dev\u001b[39m   \u001b[90m- \u001b[39m\u001b[34mtextshaping\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[36mlibharfbuzz-dev\u001b[39m  \u001b[90m- \u001b[39m\u001b[34mtextshaping\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Getting 102 pkgs (68.12 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34maskpass\u001b[34m\u001b[39m 1.2.0 (source) (6.04 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbackports\u001b[34m\u001b[39m 1.4.1 (source) (26.20 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbase64enc\u001b[34m\u001b[39m 0.1-3 (source) (7.83 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcachem\u001b[34m\u001b[39m 1.0.8 (source) (26.51 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mclipr\u001b[34m\u001b[39m 0.8.0 (source) (21.90 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcpp11\u001b[34m\u001b[39m 0.4.7 (source) (285.78 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mdigest\u001b[34m\u001b[39m 0.6.35 (source) (230.39 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfastmap\u001b[34m\u001b[39m 1.1.1 (source) (46.41 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbroom\u001b[34m\u001b[39m 1.0.5 (source) (641.85 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mforcats\u001b[34m\u001b[39m 1.0.0 (source) (294.18 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mglue\u001b[34m\u001b[39m 1.7.0 (source) (105.42 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhighr\u001b[34m\u001b[39m 0.10 (source) (15.08 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhms\u001b[34m\u001b[39m 1.1.3 (source) (43.38 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mids\u001b[34m\u001b[39m 1.0.1 (source) (91.21 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mlifecycle\u001b[34m\u001b[39m 1.0.4 (source) (107.66 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mdplyr\u001b[34m\u001b[39m 1.1.4 (source) (1.21 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mmodelr\u001b[34m\u001b[39m 0.1.11 (source) (121.48 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mpkgconfig\u001b[34m\u001b[39m 2.0.3 (source) (6.08 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrappdirs\u001b[34m\u001b[39m 0.3.3 (source) (12.29 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mps\u001b[34m\u001b[39m 1.7.6 (source) (129.49 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mreadr\u001b[34m\u001b[39m 2.1.5 (source) (298.06 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mscales\u001b[34m\u001b[39m 1.3.0 (source) (302.54 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34msys\u001b[34m\u001b[39m 3.4.2 (source) (20.17 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtextshaping\u001b[34m\u001b[39m 0.3.7 (source) (35.10 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtimechange\u001b[34m\u001b[39m 0.3.0 (source) (103.44 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrlang\u001b[34m\u001b[39m 1.1.3 (source) (763.76 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mxml2\u001b[34m\u001b[39m 1.3.6 (source) (294.71 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mvctrs\u001b[34m\u001b[39m 0.6.5 (source) (969.07 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mvroom\u001b[34m\u001b[39m 1.6.5 (source) (750.42 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mconflicted\u001b[34m\u001b[39m 1.2.0 (source) (17.07 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrmarkdown\u001b[34m\u001b[39m 2.26 (source) (2.19 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mellipsis\u001b[34m\u001b[39m 0.3.2 (source) (8.07 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcurl\u001b[34m\u001b[39m 5.2.1 (source) (716.70 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mdbplyr\u001b[34m\u001b[39m 2.5.0 (source) (770.65 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfarver\u001b[34m\u001b[39m 2.1.1 (source) (1.27 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mdata.table\u001b[34m\u001b[39m 1.15.4 (source) (5.39 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mgtable\u001b[34m\u001b[39m 0.3.5 (source) (130.23 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfs\u001b[34m\u001b[39m 1.6.4 (source) (1.20 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mjquerylib\u001b[34m\u001b[39m 0.1.4 (source) (520.21 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mlubridate\u001b[34m\u001b[39m 1.9.3 (source) (428.04 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mknitr\u001b[34m\u001b[39m 1.46 (source) (471.55 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mmemoise\u001b[34m\u001b[39m 2.0.1 (source) (17.85 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mmunsell\u001b[34m\u001b[39m 0.5.1 (source) (182.31 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mgoogledrive\u001b[34m\u001b[39m 2.1.1 (source) (1.61 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mpurrr\u001b[34m\u001b[39m 1.0.2 (source) (220.87 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrstudioapi\u001b[34m\u001b[39m 0.16.0 (source) (117.42 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mopenssl\u001b[34m\u001b[39m 2.1.2 (source) (1.21 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtzdb\u001b[34m\u001b[39m 0.4.0 (source) (586.33 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34muuid\u001b[34m\u001b[39m 1.2-0 (source) (79.72 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mwithr\u001b[34m\u001b[39m 3.0.0 (source) (107.68 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mblob\u001b[34m\u001b[39m 1.2.4 (source) (10.62 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcellranger\u001b[34m\u001b[39m 1.1.0 (source) (63.86 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtidyverse\u001b[34m\u001b[39m 2.0.0 (source) (704.62 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mdtplyr\u001b[34m\u001b[39m 1.3.1 (source) (150.97 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mgenerics\u001b[34m\u001b[39m 0.1.3 (source) (172.20 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbslib\u001b[34m\u001b[39m 0.7.0 (source) (5.13 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhtmltools\u001b[34m\u001b[39m 0.5.8.1 (source) (135.13 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mgooglesheets4\u001b[34m\u001b[39m 1.1.1 (source) (232.58 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mmagrittr\u001b[34m\u001b[39m 2.0.3 (source) (267.07 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcli\u001b[34m\u001b[39m 3.6.2 (source) (569.77 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mpillar\u001b[34m\u001b[39m 1.9.0 (source) (444.53 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mRColorBrewer\u001b[34m\u001b[39m 1.1-3 (source) (11.64 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mreadxl\u001b[34m\u001b[39m 1.4.3 (source) (2.09 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mselectr\u001b[34m\u001b[39m 0.4-2 (source) (41.37 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrvest\u001b[34m\u001b[39m 1.0.4 (source) (115.88 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mjsonlite\u001b[34m\u001b[39m 1.8.8 (source) (1.05 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mutf8\u001b[34m\u001b[39m 1.2.4 (source) (241.08 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbit64\u001b[34m\u001b[39m 4.0.5 (source) (135.09 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhttr\u001b[34m\u001b[39m 1.4.7 (source) (118.50 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mprettyunits\u001b[34m\u001b[39m 1.2.0 (source) (97.50 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtidyr\u001b[34m\u001b[39m 1.3.1 (source) (809.06 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrematch2\u001b[34m\u001b[39m 2.1.2 (source) (13.37 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mR6\u001b[34m\u001b[39m 2.5.1 (source) (63.42 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mbit\u001b[34m\u001b[39m 4.0.5 (source) (827.75 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtinytex\u001b[34m\u001b[39m 0.50 (source) (34.31 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mevaluate\u001b[34m\u001b[39m 0.23 (source) (28.35 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mgargle\u001b[34m\u001b[39m 1.5.2 (source) (627.56 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtibble\u001b[34m\u001b[39m 3.2.1 (source) (565.98 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mlabeling\u001b[34m\u001b[39m 0.4.3 (source) (10.17 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhaven\u001b[34m\u001b[39m 2.5.4 (source) (313.33 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mprogress\u001b[34m\u001b[39m 1.2.3 (source) (30.50 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mstringr\u001b[34m\u001b[39m 1.5.1 (source) (176.60 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcrayon\u001b[34m\u001b[39m 1.5.2 (source) (40.57 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mmime\u001b[34m\u001b[39m 0.12 (source) (12.56 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mviridisLite\u001b[34m\u001b[39m 0.4.2 (source) (1.27 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mrematch\u001b[34m\u001b[39m 2.0.0 (source) (4.78 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34msystemfonts\u001b[34m\u001b[39m 1.0.6 (source) (80.84 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcallr\u001b[34m\u001b[39m 3.7.6 (source) (104.36 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mprocessx\u001b[34m\u001b[39m 3.8.4 (source) (163.98 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mreprex\u001b[34m\u001b[39m 2.1.0 (source) (1.09 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mstringi\u001b[34m\u001b[39m 1.8.3 (source) (11.92 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcolorspace\u001b[34m\u001b[39m 2.1-0 (source) (2.12 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfansi\u001b[34m\u001b[39m 1.0.6 (source) (482.48 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mtidyselect\u001b[34m\u001b[39m 1.2.1 (source) (103.59 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34myaml\u001b[34m\u001b[39m 2.3.8 (source) (94.76 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfontawesome\u001b[34m\u001b[39m 0.5.2 (source) (1.28 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mxfun\u001b[34m\u001b[39m 0.43 (source) (144.50 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mragg\u001b[34m\u001b[39m 1.3.0 (source) (430.24 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mDBI\u001b[34m\u001b[39m 1.2.2 (source) (1.13 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34misoband\u001b[34m\u001b[39m 0.2.7 (source) (1.59 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34msass\u001b[34m\u001b[39m 0.4.9 (source) (3.03 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mggplot2\u001b[34m\u001b[39m 3.5.1 (source) (3.60 MB)\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Installing system requirements\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Executing `sh -c apt-get -y update`\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Executing `sh -c apt-get -y install libfribidi-dev libharfbuzz-dev`\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbackports\u001b[34m\u001b[39m 1.4.1\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbase64enc\u001b[34m\u001b[39m 0.1-3\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbit\u001b[34m\u001b[39m 4.0.5\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcli\u001b[34m\u001b[39m 3.6.2\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mclipr\u001b[34m\u001b[39m 0.8.0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcolorspace\u001b[34m\u001b[39m 2.1-0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcpp11\u001b[34m\u001b[39m 0.4.7\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcrayon\u001b[34m\u001b[39m 1.5.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbase64enc\u001b[34m\u001b[39m 0.1-3 \u001b[90m\u001b[90m(2.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcurl\u001b[34m\u001b[39m 5.2.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbackports\u001b[34m\u001b[39m 1.4.1 \u001b[90m\u001b[90m(2.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mdata.table\u001b[34m\u001b[39m 1.15.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mclipr\u001b[34m\u001b[39m 0.8.0 \u001b[90m\u001b[90m(3.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mDBI\u001b[34m\u001b[39m 1.2.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcpp11\u001b[34m\u001b[39m 0.4.7 \u001b[90m\u001b[90m(3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mdigest\u001b[34m\u001b[39m 0.6.35\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcrayon\u001b[34m\u001b[39m 1.5.2 \u001b[90m\u001b[90m(4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mevaluate\u001b[34m\u001b[39m 0.23\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mevaluate\u001b[34m\u001b[39m 0.23 \u001b[90m\u001b[90m(3.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfansi\u001b[34m\u001b[39m 1.0.6\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcurl\u001b[34m\u001b[39m 5.2.1 \u001b[90m\u001b[90m(9.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfarver\u001b[34m\u001b[39m 2.1.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbit\u001b[34m\u001b[39m 4.0.5 \u001b[90m\u001b[90m(13.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfastmap\u001b[34m\u001b[39m 1.1.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mDBI\u001b[34m\u001b[39m 1.2.2 \u001b[90m\u001b[90m(9.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfs\u001b[34m\u001b[39m 1.6.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcolorspace\u001b[34m\u001b[39m 2.1-0 \u001b[90m\u001b[90m(15s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mgenerics\u001b[34m\u001b[39m 0.1.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfansi\u001b[34m\u001b[39m 1.0.6 \u001b[90m\u001b[90m(9.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mglue\u001b[34m\u001b[39m 1.7.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mgenerics\u001b[34m\u001b[39m 0.1.3 \u001b[90m\u001b[90m(3.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34misoband\u001b[34m\u001b[39m 0.2.7\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mdigest\u001b[34m\u001b[39m 0.6.35 \u001b[90m\u001b[90m(15.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mjsonlite\u001b[34m\u001b[39m 1.8.8\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfastmap\u001b[34m\u001b[39m 1.1.1 \u001b[90m\u001b[90m(7.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mlabeling\u001b[34m\u001b[39m 0.4.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mglue\u001b[34m\u001b[39m 1.7.0 \u001b[90m\u001b[90m(4.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mmagrittr\u001b[34m\u001b[39m 2.0.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcli\u001b[34m\u001b[39m 3.6.2 \u001b[90m\u001b[90m(23.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mmime\u001b[34m\u001b[39m 0.12\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mlabeling\u001b[34m\u001b[39m 0.4.3 \u001b[90m\u001b[90m(3.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mpkgconfig\u001b[34m\u001b[39m 2.0.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mmime\u001b[34m\u001b[39m 0.12 \u001b[90m\u001b[90m(2.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mpkgconfig\u001b[34m\u001b[39m 2.0.3 \u001b[90m\u001b[90m(2.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mprettyunits\u001b[34m\u001b[39m 1.2.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mmagrittr\u001b[34m\u001b[39m 2.0.3 \u001b[90m\u001b[90m(3.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mps\u001b[34m\u001b[39m 1.7.6\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mR6\u001b[34m\u001b[39m 2.5.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mprettyunits\u001b[34m\u001b[39m 1.2.0 \u001b[90m\u001b[90m(2.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrappdirs\u001b[34m\u001b[39m 0.3.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mR6\u001b[34m\u001b[39m 2.5.1 \u001b[90m\u001b[90m(2.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mRColorBrewer\u001b[34m\u001b[39m 1.1-3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mjsonlite\u001b[34m\u001b[39m 1.8.8 \u001b[90m\u001b[90m(10s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrematch\u001b[34m\u001b[39m 2.0.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34misoband\u001b[34m\u001b[39m 0.2.7 \u001b[90m\u001b[90m(12.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrlang\u001b[34m\u001b[39m 1.1.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrappdirs\u001b[34m\u001b[39m 0.3.3 \u001b[90m\u001b[90m(2.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrematch\u001b[34m\u001b[39m 2.0.0 \u001b[90m\u001b[90m(2.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrstudioapi\u001b[34m\u001b[39m 0.16.0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mstringi\u001b[34m\u001b[39m 1.8.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mRColorBrewer\u001b[34m\u001b[39m 1.1-3 \u001b[90m\u001b[90m(4.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34msys\u001b[34m\u001b[39m 3.4.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrstudioapi\u001b[34m\u001b[39m 0.16.0 \u001b[90m\u001b[90m(4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mutf8\u001b[34m\u001b[39m 1.2.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mps\u001b[34m\u001b[39m 1.7.6 \u001b[90m\u001b[90m(10.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34muuid\u001b[34m\u001b[39m 1.2-0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34msys\u001b[34m\u001b[39m 3.4.2 \u001b[90m\u001b[90m(3.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mviridisLite\u001b[34m\u001b[39m 0.4.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mviridisLite\u001b[34m\u001b[39m 0.4.2 \u001b[90m\u001b[90m(2.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mwithr\u001b[34m\u001b[39m 3.0.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mwithr\u001b[34m\u001b[39m 3.0.0 \u001b[90m\u001b[90m(3.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mxfun\u001b[34m\u001b[39m 0.43\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mutf8\u001b[34m\u001b[39m 1.2.4 \u001b[90m\u001b[90m(8.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34myaml\u001b[34m\u001b[39m 2.3.8\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34muuid\u001b[34m\u001b[39m 1.2-0 \u001b[90m\u001b[90m(12s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbackports\u001b[34m\u001b[39m 1.4.1  \u001b[90m\u001b[90m(118ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbase64enc\u001b[34m\u001b[39m 0.1-3  \u001b[90m\u001b[90m(60ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbit\u001b[34m\u001b[39m 4.0.5  \u001b[90m\u001b[90m(138ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbit64\u001b[34m\u001b[39m 4.0.5\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mxfun\u001b[34m\u001b[39m 0.43 \u001b[90m\u001b[90m(10s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcli\u001b[34m\u001b[39m 3.6.2  \u001b[90m\u001b[90m(107ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mclipr\u001b[34m\u001b[39m 0.8.0  \u001b[90m\u001b[90m(53ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcolorspace\u001b[34m\u001b[39m 2.1-0  \u001b[90m\u001b[90m(174ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mmunsell\u001b[34m\u001b[39m 0.5.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mdata.table\u001b[34m\u001b[39m 1.15.4 \u001b[90m\u001b[90m(55.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcpp11\u001b[34m\u001b[39m 0.4.7  \u001b[90m\u001b[90m(76ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34msystemfonts\u001b[34m\u001b[39m 1.0.6\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34myaml\u001b[34m\u001b[39m 2.3.8 \u001b[90m\u001b[90m(13.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtimechange\u001b[34m\u001b[39m 0.3.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mmunsell\u001b[34m\u001b[39m 0.5.1 \u001b[90m\u001b[90m(4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtzdb\u001b[34m\u001b[39m 0.4.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfarver\u001b[34m\u001b[39m 2.1.1 \u001b[90m\u001b[90m(50.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcrayon\u001b[34m\u001b[39m 1.5.2  \u001b[90m\u001b[90m(52ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcurl\u001b[34m\u001b[39m 5.2.1  \u001b[90m\u001b[90m(87ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mdata.table\u001b[34m\u001b[39m 1.15.4  \u001b[90m\u001b[90m(149ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mDBI\u001b[34m\u001b[39m 1.2.2  \u001b[90m\u001b[90m(98ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mdigest\u001b[34m\u001b[39m 0.6.35  \u001b[90m\u001b[90m(93ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mevaluate\u001b[34m\u001b[39m 0.23  \u001b[90m\u001b[90m(69ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfansi\u001b[34m\u001b[39m 1.0.6  \u001b[90m\u001b[90m(74ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfarver\u001b[34m\u001b[39m 2.1.1  \u001b[90m\u001b[90m(148ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfastmap\u001b[34m\u001b[39m 1.1.1  \u001b[90m\u001b[90m(78ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mgenerics\u001b[34m\u001b[39m 0.1.3  \u001b[90m\u001b[90m(68ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mglue\u001b[34m\u001b[39m 1.7.0  \u001b[90m\u001b[90m(96ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34misoband\u001b[34m\u001b[39m 0.2.7  \u001b[90m\u001b[90m(161ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrlang\u001b[34m\u001b[39m 1.1.3 \u001b[90m\u001b[90m(31.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mjsonlite\u001b[34m\u001b[39m 1.8.8  \u001b[90m\u001b[90m(170ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mlabeling\u001b[34m\u001b[39m 0.4.3  \u001b[90m\u001b[90m(170ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mmagrittr\u001b[34m\u001b[39m 2.0.3  \u001b[90m\u001b[90m(226ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mmime\u001b[34m\u001b[39m 0.12  \u001b[90m\u001b[90m(228ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mmunsell\u001b[34m\u001b[39m 0.5.1  \u001b[90m\u001b[90m(171ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mpkgconfig\u001b[34m\u001b[39m 2.0.3  \u001b[90m\u001b[90m(178ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mprettyunits\u001b[34m\u001b[39m 1.2.0  \u001b[90m\u001b[90m(220ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mps\u001b[34m\u001b[39m 1.7.6  \u001b[90m\u001b[90m(218ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mR6\u001b[34m\u001b[39m 2.5.1  \u001b[90m\u001b[90m(175ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mprocessx\u001b[34m\u001b[39m 3.8.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrappdirs\u001b[34m\u001b[39m 0.3.3  \u001b[90m\u001b[90m(454ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mRColorBrewer\u001b[34m\u001b[39m 1.1-3  \u001b[90m\u001b[90m(74ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrematch\u001b[34m\u001b[39m 2.0.0  \u001b[90m\u001b[90m(51ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrlang\u001b[34m\u001b[39m 1.1.3  \u001b[90m\u001b[90m(116ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcachem\u001b[34m\u001b[39m 1.0.8\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbit64\u001b[34m\u001b[39m 4.0.5 \u001b[90m\u001b[90m(18.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mellipsis\u001b[34m\u001b[39m 0.3.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcachem\u001b[34m\u001b[39m 1.0.8 \u001b[90m\u001b[90m(4.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhtmltools\u001b[34m\u001b[39m 0.5.8.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mellipsis\u001b[34m\u001b[39m 0.3.2 \u001b[90m\u001b[90m(3.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mlifecycle\u001b[34m\u001b[39m 1.0.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfs\u001b[34m\u001b[39m 1.6.4 \u001b[90m\u001b[90m(1m 0.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mxml2\u001b[34m\u001b[39m 1.3.6\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mlifecycle\u001b[34m\u001b[39m 1.0.4 \u001b[90m\u001b[90m(4.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbit64\u001b[34m\u001b[39m 4.0.5  \u001b[90m\u001b[90m(71ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcachem\u001b[34m\u001b[39m 1.0.8  \u001b[90m\u001b[90m(64ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mmemoise\u001b[34m\u001b[39m 2.0.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mprocessx\u001b[34m\u001b[39m 3.8.4 \u001b[90m\u001b[90m(13.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mellipsis\u001b[34m\u001b[39m 0.3.2  \u001b[90m\u001b[90m(47ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfs\u001b[34m\u001b[39m 1.6.4  \u001b[90m\u001b[90m(200ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mlifecycle\u001b[34m\u001b[39m 1.0.4  \u001b[90m\u001b[90m(128ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mgtable\u001b[34m\u001b[39m 0.3.5\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhtmltools\u001b[34m\u001b[39m 0.5.8.1 \u001b[90m\u001b[90m(10.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mvctrs\u001b[34m\u001b[39m 0.6.5\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mmemoise\u001b[34m\u001b[39m 2.0.1 \u001b[90m\u001b[90m(5.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhtmltools\u001b[34m\u001b[39m 0.5.8.1  \u001b[90m\u001b[90m(82ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfontawesome\u001b[34m\u001b[39m 0.5.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mgtable\u001b[34m\u001b[39m 0.3.5 \u001b[90m\u001b[90m(5.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mjquerylib\u001b[34m\u001b[39m 0.1.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfontawesome\u001b[34m\u001b[39m 0.5.2 \u001b[90m\u001b[90m(5.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34msass\u001b[34m\u001b[39m 0.4.9\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mjquerylib\u001b[34m\u001b[39m 0.1.4 \u001b[90m\u001b[90m(4.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfontawesome\u001b[34m\u001b[39m 0.5.2  \u001b[90m\u001b[90m(126ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mgtable\u001b[34m\u001b[39m 0.3.5  \u001b[90m\u001b[90m(76ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mjquerylib\u001b[34m\u001b[39m 0.1.4  \u001b[90m\u001b[90m(95ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mmemoise\u001b[34m\u001b[39m 2.0.1  \u001b[90m\u001b[90m(130ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mconflicted\u001b[34m\u001b[39m 1.2.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mconflicted\u001b[34m\u001b[39m 1.2.0 \u001b[90m\u001b[90m(4.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mconflicted\u001b[34m\u001b[39m 1.2.0  \u001b[90m\u001b[90m(85ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mprocessx\u001b[34m\u001b[39m 3.8.4  \u001b[90m\u001b[90m(101ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcallr\u001b[34m\u001b[39m 3.7.6\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtzdb\u001b[34m\u001b[39m 0.4.0 \u001b[90m\u001b[90m(37.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrstudioapi\u001b[34m\u001b[39m 0.16.0  \u001b[90m\u001b[90m(65ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34msys\u001b[34m\u001b[39m 3.4.2  \u001b[90m\u001b[90m(61ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34maskpass\u001b[34m\u001b[39m 1.2.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mxml2\u001b[34m\u001b[39m 1.3.6 \u001b[90m\u001b[90m(24.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtzdb\u001b[34m\u001b[39m 0.4.0  \u001b[90m\u001b[90m(152ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mutf8\u001b[34m\u001b[39m 1.2.4  \u001b[90m\u001b[90m(134ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34muuid\u001b[34m\u001b[39m 1.2-0  \u001b[90m\u001b[90m(60ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mviridisLite\u001b[34m\u001b[39m 0.4.2  \u001b[90m\u001b[90m(94ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mscales\u001b[34m\u001b[39m 1.3.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34maskpass\u001b[34m\u001b[39m 1.2.0 \u001b[90m\u001b[90m(3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34maskpass\u001b[34m\u001b[39m 1.2.0  \u001b[90m\u001b[90m(64ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mopenssl\u001b[34m\u001b[39m 2.1.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcallr\u001b[34m\u001b[39m 3.7.6 \u001b[90m\u001b[90m(11.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcallr\u001b[34m\u001b[39m 3.7.6  \u001b[90m\u001b[90m(1.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mwithr\u001b[34m\u001b[39m 3.0.0  \u001b[90m\u001b[90m(129ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mxfun\u001b[34m\u001b[39m 0.43  \u001b[90m\u001b[90m(56ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhighr\u001b[34m\u001b[39m 0.10\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtimechange\u001b[34m\u001b[39m 0.3.0 \u001b[90m\u001b[90m(52.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtinytex\u001b[34m\u001b[39m 0.50\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhighr\u001b[34m\u001b[39m 0.10 \u001b[90m\u001b[90m(2.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhighr\u001b[34m\u001b[39m 0.10  \u001b[90m\u001b[90m(54ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtimechange\u001b[34m\u001b[39m 0.3.0  \u001b[90m\u001b[90m(209ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mlubridate\u001b[34m\u001b[39m 1.9.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mscales\u001b[34m\u001b[39m 1.3.0 \u001b[90m\u001b[90m(12.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mscales\u001b[34m\u001b[39m 1.3.0  \u001b[90m\u001b[90m(76ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mxml2\u001b[34m\u001b[39m 1.3.6  \u001b[90m\u001b[90m(89ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34myaml\u001b[34m\u001b[39m 2.3.8  \u001b[90m\u001b[90m(61ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mknitr\u001b[34m\u001b[39m 1.46\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtinytex\u001b[34m\u001b[39m 0.50 \u001b[90m\u001b[90m(4.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtinytex\u001b[34m\u001b[39m 0.50  \u001b[90m\u001b[90m(61ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mopenssl\u001b[34m\u001b[39m 2.1.2 \u001b[90m\u001b[90m(16s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mopenssl\u001b[34m\u001b[39m 2.1.2  \u001b[90m\u001b[90m(112ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhttr\u001b[34m\u001b[39m 1.4.7\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mids\u001b[34m\u001b[39m 1.0.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mids\u001b[34m\u001b[39m 1.0.1 \u001b[90m\u001b[90m(3.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mids\u001b[34m\u001b[39m 1.0.1  \u001b[90m\u001b[90m(1.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34msystemfonts\u001b[34m\u001b[39m 1.0.6 \u001b[90m\u001b[90m(1m 6.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34msystemfonts\u001b[34m\u001b[39m 1.0.6  \u001b[90m\u001b[90m(149ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtextshaping\u001b[34m\u001b[39m 0.3.7\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhttr\u001b[34m\u001b[39m 1.4.7 \u001b[90m\u001b[90m(10s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhttr\u001b[34m\u001b[39m 1.4.7  \u001b[90m\u001b[90m(63ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mgargle\u001b[34m\u001b[39m 1.5.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mlubridate\u001b[34m\u001b[39m 1.9.3 \u001b[90m\u001b[90m(17.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mlubridate\u001b[34m\u001b[39m 1.9.3  \u001b[90m\u001b[90m(143ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mknitr\u001b[34m\u001b[39m 1.46 \u001b[90m\u001b[90m(16.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mknitr\u001b[34m\u001b[39m 1.46  \u001b[90m\u001b[90m(134ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mvctrs\u001b[34m\u001b[39m 0.6.5 \u001b[90m\u001b[90m(54.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mvctrs\u001b[34m\u001b[39m 0.6.5  \u001b[90m\u001b[90m(88ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mblob\u001b[34m\u001b[39m 1.2.4\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhms\u001b[34m\u001b[39m 1.1.3\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mpillar\u001b[34m\u001b[39m 1.9.0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mpurrr\u001b[34m\u001b[39m 1.0.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mgargle\u001b[34m\u001b[39m 1.5.2 \u001b[90m\u001b[90m(9.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtidyselect\u001b[34m\u001b[39m 1.2.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mblob\u001b[34m\u001b[39m 1.2.4 \u001b[90m\u001b[90m(4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mblob\u001b[34m\u001b[39m 1.2.4  \u001b[90m\u001b[90m(55ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mgargle\u001b[34m\u001b[39m 1.5.2  \u001b[90m\u001b[90m(88ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhms\u001b[34m\u001b[39m 1.1.3 \u001b[90m\u001b[90m(4.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhms\u001b[34m\u001b[39m 1.1.3  \u001b[90m\u001b[90m(56ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mprogress\u001b[34m\u001b[39m 1.2.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtidyselect\u001b[34m\u001b[39m 1.2.1 \u001b[90m\u001b[90m(5.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtidyselect\u001b[34m\u001b[39m 1.2.1  \u001b[90m\u001b[90m(61ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mprogress\u001b[34m\u001b[39m 1.2.3 \u001b[90m\u001b[90m(4.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mprogress\u001b[34m\u001b[39m 1.2.3  \u001b[90m\u001b[90m(44ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mpillar\u001b[34m\u001b[39m 1.9.0 \u001b[90m\u001b[90m(10s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mpillar\u001b[34m\u001b[39m 1.9.0  \u001b[90m\u001b[90m(76ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtibble\u001b[34m\u001b[39m 3.2.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mpurrr\u001b[34m\u001b[39m 1.0.2 \u001b[90m\u001b[90m(10.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mpurrr\u001b[34m\u001b[39m 1.0.2  \u001b[90m\u001b[90m(1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtextshaping\u001b[34m\u001b[39m 0.3.7 \u001b[90m\u001b[90m(23.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtextshaping\u001b[34m\u001b[39m 0.3.7  \u001b[90m\u001b[90m(1.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mragg\u001b[34m\u001b[39m 1.3.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtibble\u001b[34m\u001b[39m 3.2.1 \u001b[90m\u001b[90m(6.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtibble\u001b[34m\u001b[39m 3.2.1  \u001b[90m\u001b[90m(116ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcellranger\u001b[34m\u001b[39m 1.1.0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mdplyr\u001b[34m\u001b[39m 1.1.4\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mforcats\u001b[34m\u001b[39m 1.0.0\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mggplot2\u001b[34m\u001b[39m 3.5.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcellranger\u001b[34m\u001b[39m 1.1.0 \u001b[90m\u001b[90m(2.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mgoogledrive\u001b[34m\u001b[39m 2.1.1\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrematch2\u001b[34m\u001b[39m 2.1.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mforcats\u001b[34m\u001b[39m 1.0.0 \u001b[90m\u001b[90m(5.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mvroom\u001b[34m\u001b[39m 1.6.5\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrematch2\u001b[34m\u001b[39m 2.1.2 \u001b[90m\u001b[90m(4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcellranger\u001b[34m\u001b[39m 1.1.0  \u001b[90m\u001b[90m(61ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mreadxl\u001b[34m\u001b[39m 1.4.3\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mgoogledrive\u001b[34m\u001b[39m 2.1.1 \u001b[90m\u001b[90m(10.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mforcats\u001b[34m\u001b[39m 1.0.0  \u001b[90m\u001b[90m(92ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mgoogledrive\u001b[34m\u001b[39m 2.1.1  \u001b[90m\u001b[90m(93ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrematch2\u001b[34m\u001b[39m 2.1.2  \u001b[90m\u001b[90m(59ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mgooglesheets4\u001b[34m\u001b[39m 1.1.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mgooglesheets4\u001b[34m\u001b[39m 1.1.1 \u001b[90m\u001b[90m(10s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mgooglesheets4\u001b[34m\u001b[39m 1.1.1  \u001b[90m\u001b[90m(64ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mdplyr\u001b[34m\u001b[39m 1.1.4 \u001b[90m\u001b[90m(29.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mdplyr\u001b[34m\u001b[39m 1.1.4  \u001b[90m\u001b[90m(92ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mdtplyr\u001b[34m\u001b[39m 1.3.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mdtplyr\u001b[34m\u001b[39m 1.3.1 \u001b[90m\u001b[90m(8.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mdtplyr\u001b[34m\u001b[39m 1.3.1  \u001b[90m\u001b[90m(67ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mggplot2\u001b[34m\u001b[39m 3.5.1 \u001b[90m\u001b[90m(41s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mggplot2\u001b[34m\u001b[39m 3.5.1  \u001b[90m\u001b[90m(181ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mreadxl\u001b[34m\u001b[39m 1.4.3 \u001b[90m\u001b[90m(39.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mreadxl\u001b[34m\u001b[39m 1.4.3  \u001b[90m\u001b[90m(130ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mstringi\u001b[34m\u001b[39m 1.8.3 \u001b[90m\u001b[90m(3m 1.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mstringi\u001b[34m\u001b[39m 1.8.3  \u001b[90m\u001b[90m(126ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mstringr\u001b[34m\u001b[39m 1.5.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mstringr\u001b[34m\u001b[39m 1.5.1 \u001b[90m\u001b[90m(3.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mstringr\u001b[34m\u001b[39m 1.5.1  \u001b[90m\u001b[90m(1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mselectr\u001b[34m\u001b[39m 0.4-2\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtidyr\u001b[34m\u001b[39m 1.3.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mselectr\u001b[34m\u001b[39m 0.4-2 \u001b[90m\u001b[90m(11.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mselectr\u001b[34m\u001b[39m 0.4-2  \u001b[90m\u001b[90m(60ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrvest\u001b[34m\u001b[39m 1.0.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrvest\u001b[34m\u001b[39m 1.0.4 \u001b[90m\u001b[90m(5.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrvest\u001b[34m\u001b[39m 1.0.4  \u001b[90m\u001b[90m(42ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtidyr\u001b[34m\u001b[39m 1.3.1 \u001b[90m\u001b[90m(17.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtidyr\u001b[34m\u001b[39m 1.3.1  \u001b[90m\u001b[90m(64ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbroom\u001b[34m\u001b[39m 1.0.5\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mdbplyr\u001b[34m\u001b[39m 2.5.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbroom\u001b[34m\u001b[39m 1.0.5 \u001b[90m\u001b[90m(13.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbroom\u001b[34m\u001b[39m 1.0.5  \u001b[90m\u001b[90m(125ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mmodelr\u001b[34m\u001b[39m 0.1.11\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mmodelr\u001b[34m\u001b[39m 0.1.11 \u001b[90m\u001b[90m(3.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mmodelr\u001b[34m\u001b[39m 0.1.11  \u001b[90m\u001b[90m(1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mdbplyr\u001b[34m\u001b[39m 2.5.0 \u001b[90m\u001b[90m(18.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mdbplyr\u001b[34m\u001b[39m 2.5.0  \u001b[90m\u001b[90m(63ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34msass\u001b[34m\u001b[39m 0.4.9 \u001b[90m\u001b[90m(3m 30.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34msass\u001b[34m\u001b[39m 0.4.9  \u001b[90m\u001b[90m(153ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mbslib\u001b[34m\u001b[39m 0.7.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mvroom\u001b[34m\u001b[39m 1.6.5 \u001b[90m\u001b[90m(2m 19.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mvroom\u001b[34m\u001b[39m 1.6.5  \u001b[90m\u001b[90m(252ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mreadr\u001b[34m\u001b[39m 2.1.5\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mbslib\u001b[34m\u001b[39m 0.7.0 \u001b[90m\u001b[90m(8.9s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mbslib\u001b[34m\u001b[39m 0.7.0  \u001b[90m\u001b[90m(218ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mrmarkdown\u001b[34m\u001b[39m 2.26\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mrmarkdown\u001b[34m\u001b[39m 2.26 \u001b[90m\u001b[90m(9.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mrmarkdown\u001b[34m\u001b[39m 2.26  \u001b[90m\u001b[90m(126ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mreprex\u001b[34m\u001b[39m 2.1.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mreprex\u001b[34m\u001b[39m 2.1.0 \u001b[90m\u001b[90m(3.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mreprex\u001b[34m\u001b[39m 2.1.0  \u001b[90m\u001b[90m(48ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mreadr\u001b[34m\u001b[39m 2.1.5 \u001b[90m\u001b[90m(57.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mreadr\u001b[34m\u001b[39m 2.1.5  \u001b[90m\u001b[90m(116ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhaven\u001b[34m\u001b[39m 2.5.4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhaven\u001b[34m\u001b[39m 2.5.4 \u001b[90m\u001b[90m(26.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhaven\u001b[34m\u001b[39m 2.5.4  \u001b[90m\u001b[90m(73ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mragg\u001b[34m\u001b[39m 1.3.0 \u001b[90m\u001b[90m(3m 59.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mragg\u001b[34m\u001b[39m 1.3.0  \u001b[90m\u001b[90m(342ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mtidyverse\u001b[34m\u001b[39m 2.0.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mtidyverse\u001b[34m\u001b[39m 2.0.0 \u001b[90m\u001b[90m(3.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mtidyverse\u001b[34m\u001b[39m 2.0.0  \u001b[90m\u001b[90m(41ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m 1 pkg + 106 deps: kept 1, added 102, dld 102 (68.19 MB) \u001b[90m\u001b[90m[7m 19.1s]\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[33m!\u001b[39m Using bundled GitHub PAT. Please add your own PAT using `gitcreds::gitcreds_set()`.\n",
            "\n",
            " \n",
            "\n",
            "→ Will \u001b[3m\u001b[3minstall\u001b[3m\u001b[23m 15 packages.\n",
            "\n",
            "→ Will \u001b[3m\u001b[3mdownload\u001b[3m\u001b[23m 14 CRAN packages (15.46 MB), cached: 1 (0 B).\n",
            "\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcommonmark\u001b[39m        1.9.1   [bld][cmp][dl] \u001b[90m(145.98 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mcrosstalk\u001b[39m         1.2.1   [bld][dl] \u001b[90m(297.97 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mDT\u001b[39m                0.33    [bld][dl] \u001b[90m(1.68 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mfingertipsR\u001b[39m       1.0.12  [bld][cmp] (GitHub: 309c4ae)\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhtmlwidgets\u001b[39m       1.6.4   [bld][dl] \u001b[90m(868.89 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mhttpuv\u001b[39m            1.6.15  [bld][cmp][dl] \u001b[90m(1.88 MB)\u001b[39m\u001b[90m + \u001b[39m\u001b[36m\u001b[32m✔\u001b[36m make\u001b[39m, \u001b[36m\u001b[32m✔\u001b[36m zlib1g-dev\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mlater\u001b[39m             1.3.2   [bld][cmp][dl] \u001b[90m(63.60 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mlazyeval\u001b[39m          0.2.2   [bld][cmp][dl] \u001b[90m(83.48 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mminiUI\u001b[39m            0.1.1.1 [bld][dl] \u001b[90m(97.96 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mpromises\u001b[39m          1.3.0   [bld][cmp][dl] \u001b[90m(3.16 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mRcpp\u001b[39m              1.0.12  [bld][cmp][dl] \u001b[90m(3.43 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mshiny\u001b[39m             1.8.1.1 [bld][dl] \u001b[90m(3.05 MB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mshinycssloaders\u001b[39m   1.0.0   [bld][dl] \u001b[90m(122.97 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34msourcetools\u001b[39m       0.1.7-1 [bld][cmp][dl] \u001b[90m(24.09 kB)\u001b[39m\n",
            "\u001b[90m+ \u001b[39m\u001b[34mxtable\u001b[39m            1.8-4   [bld][dl] \u001b[90m(564.59 kB)\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m All system requirements are already installed.\n",
            "\n",
            "  \n",
            "\n",
            "\u001b[36mℹ\u001b[39m Getting 14 pkgs (15.46 MB), 1 cached\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcommonmark\u001b[34m\u001b[39m 1.9.1 (source) (145.98 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mcrosstalk\u001b[34m\u001b[39m 1.2.1 (source) (297.97 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34msourcetools\u001b[34m\u001b[39m 0.1.7-1 (source) (24.09 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mminiUI\u001b[34m\u001b[39m 0.1.1.1 (source) (97.96 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mlazyeval\u001b[34m\u001b[39m 0.2.2 (source) (83.48 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mxtable\u001b[34m\u001b[39m 1.8-4 (source) (564.59 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mlater\u001b[34m\u001b[39m 1.3.2 (source) (63.60 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mshinycssloaders\u001b[34m\u001b[39m 1.0.0 (source) (122.97 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mDT\u001b[34m\u001b[39m 0.33 (source) (1.68 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12 (source) (143.78 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhttpuv\u001b[34m\u001b[39m 1.6.15 (source) (1.88 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mhtmlwidgets\u001b[34m\u001b[39m 1.6.4 (source) (868.89 kB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mpromises\u001b[34m\u001b[39m 1.3.0 (source) (3.16 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mshiny\u001b[34m\u001b[39m 1.8.1.1 (source) (3.05 MB)\n",
            "\n",
            "\u001b[32m✔\u001b[39m Got \u001b[34m\u001b[34mRcpp\u001b[34m\u001b[39m 1.0.12 (source) (3.43 MB)\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcommonmark\u001b[34m\u001b[39m 1.9.1\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhtmlwidgets\u001b[34m\u001b[39m 1.6.4\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mlazyeval\u001b[34m\u001b[39m 0.2.2\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mRcpp\u001b[34m\u001b[39m 1.0.12\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34msourcetools\u001b[34m\u001b[39m 0.1.7-1\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mxtable\u001b[34m\u001b[39m 1.8-4\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mlazyeval\u001b[34m\u001b[39m 0.2.2 \u001b[90m\u001b[90m(3.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhtmlwidgets\u001b[34m\u001b[39m 1.6.4 \u001b[90m\u001b[90m(3.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mlazyeval\u001b[34m\u001b[39m 0.2.2  \u001b[90m\u001b[90m(153ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mcrosstalk\u001b[34m\u001b[39m 1.2.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhtmlwidgets\u001b[34m\u001b[39m 1.6.4  \u001b[90m\u001b[90m(310ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mxtable\u001b[34m\u001b[39m 1.8-4 \u001b[90m\u001b[90m(3.3s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mxtable\u001b[34m\u001b[39m 1.8-4  \u001b[90m\u001b[90m(1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34msourcetools\u001b[34m\u001b[39m 0.1.7-1 \u001b[90m\u001b[90m(6.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34msourcetools\u001b[34m\u001b[39m 0.1.7-1  \u001b[90m\u001b[90m(1.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcrosstalk\u001b[34m\u001b[39m 1.2.1 \u001b[90m\u001b[90m(4.8s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcrosstalk\u001b[34m\u001b[39m 1.2.1  \u001b[90m\u001b[90m(51ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mcommonmark\u001b[34m\u001b[39m 1.9.1 \u001b[90m\u001b[90m(17.6s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mcommonmark\u001b[34m\u001b[39m 1.9.1  \u001b[90m\u001b[90m(43ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mRcpp\u001b[34m\u001b[39m 1.0.12 \u001b[90m\u001b[90m(44.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mRcpp\u001b[34m\u001b[39m 1.0.12  \u001b[90m\u001b[90m(173ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mlater\u001b[34m\u001b[39m 1.3.2\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mlater\u001b[34m\u001b[39m 1.3.2 \u001b[90m\u001b[90m(27.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mlater\u001b[34m\u001b[39m 1.3.2  \u001b[90m\u001b[90m(56ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mpromises\u001b[34m\u001b[39m 1.3.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mpromises\u001b[34m\u001b[39m 1.3.0 \u001b[90m\u001b[90m(14.2s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mpromises\u001b[34m\u001b[39m 1.3.0  \u001b[90m\u001b[90m(70ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mhttpuv\u001b[34m\u001b[39m 1.6.15\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mhttpuv\u001b[34m\u001b[39m 1.6.15 \u001b[90m\u001b[90m(2m 47.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mhttpuv\u001b[34m\u001b[39m 1.6.15  \u001b[90m\u001b[90m(162ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mDT\u001b[34m\u001b[39m 0.33\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mshiny\u001b[34m\u001b[39m 1.8.1.1\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mDT\u001b[34m\u001b[39m 0.33 \u001b[90m\u001b[90m(4.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mDT\u001b[34m\u001b[39m 0.33  \u001b[90m\u001b[90m(108ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mshiny\u001b[34m\u001b[39m 1.8.1.1 \u001b[90m\u001b[90m(24.5s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mshiny\u001b[34m\u001b[39m 1.8.1.1  \u001b[90m\u001b[90m(170ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mminiUI\u001b[34m\u001b[39m 0.1.1.1\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mshinycssloaders\u001b[34m\u001b[39m 1.0.0\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mshinycssloaders\u001b[34m\u001b[39m 1.0.0 \u001b[90m\u001b[90m(1.7s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mshinycssloaders\u001b[34m\u001b[39m 1.0.0  \u001b[90m\u001b[90m(32ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mminiUI\u001b[34m\u001b[39m 0.1.1.1 \u001b[90m\u001b[90m(2.4s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mminiUI\u001b[34m\u001b[39m 0.1.1.1  \u001b[90m\u001b[90m(32ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Packaging \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12\n",
            "\n",
            "\u001b[32m✔\u001b[39m Packaged \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12 \u001b[90m\u001b[90m(785ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[36mℹ\u001b[39m Building \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12\n",
            "\n",
            "\u001b[32m✔\u001b[39m Built \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12 \u001b[90m\u001b[90m(4.1s)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m Installed \u001b[34m\u001b[34mfingertipsR\u001b[34m\u001b[39m 1.0.12 (github::ropensci/fingertipsR@309c4ae) \u001b[90m\u001b[90m(31ms)\u001b[90m\u001b[39m\n",
            "\n",
            "\u001b[32m✔\u001b[39m 1 pkg + 64 deps: kept 50, added 15, dld 15 (NA B) \u001b[90m\u001b[90m[4m 56.4s]\u001b[90m\u001b[39m\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "  library(fingertipsR)\n",
        "  library(tidyverse)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "i7z-mYNobzmB",
        "outputId": "eb765486-efea-4218-b179-a59619abce3e"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "── \u001b[1mAttaching core tidyverse packages\u001b[22m ──────────────────────── tidyverse 2.0.0 ──\n",
            "\u001b[32m✔\u001b[39m \u001b[34mdplyr    \u001b[39m 1.1.4     \u001b[32m✔\u001b[39m \u001b[34mreadr    \u001b[39m 2.1.5\n",
            "\u001b[32m✔\u001b[39m \u001b[34mforcats  \u001b[39m 1.0.0     \u001b[32m✔\u001b[39m \u001b[34mstringr  \u001b[39m 1.5.1\n",
            "\u001b[32m✔\u001b[39m \u001b[34mggplot2  \u001b[39m 3.5.1     \u001b[32m✔\u001b[39m \u001b[34mtibble   \u001b[39m 3.2.1\n",
            "\u001b[32m✔\u001b[39m \u001b[34mlubridate\u001b[39m 1.9.3     \u001b[32m✔\u001b[39m \u001b[34mtidyr    \u001b[39m 1.3.1\n",
            "\u001b[32m✔\u001b[39m \u001b[34mpurrr    \u001b[39m 1.0.2     \n",
            "── \u001b[1mConflicts\u001b[22m ────────────────────────────────────────── tidyverse_conflicts() ──\n",
            "\u001b[31m✖\u001b[39m \u001b[34mpurrr\u001b[39m::\u001b[32m%||%()\u001b[39m   masks \u001b[34mbase\u001b[39m::%||%()\n",
            "\u001b[31m✖\u001b[39m \u001b[34mdplyr\u001b[39m::\u001b[32mfilter()\u001b[39m masks \u001b[34mstats\u001b[39m::filter()\n",
            "\u001b[31m✖\u001b[39m \u001b[34mdplyr\u001b[39m::\u001b[32mlag()\u001b[39m    masks \u001b[34mstats\u001b[39m::lag()\n",
            "\u001b[36mℹ\u001b[39m Use the conflicted package (\u001b[3m\u001b[34m<http://conflicted.r-lib.org/>\u001b[39m\u001b[23m) to force all conflicts to become errors\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "profiles() |>\n",
        "  filter(str_detect(ProfileName, \"AMR\"))\n",
        "\n",
        "amr_ind <- indicators(DomainID = 1938132908)\n",
        "\n",
        "amr_ind_id <- amr_ind$IndicatorID"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 345
        },
        "id": "ctXcpC7nb7Wp",
        "outputId": "69812141-ecbd-444a-d1cd-07dc6cc493d7"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "<table class=\"dataframe\">\n",
              "<caption>A tibble: 8 × 4</caption>\n",
              "<thead>\n",
              "\t<tr><th scope=col>ProfileID</th><th scope=col>ProfileName</th><th scope=col>DomainID</th><th scope=col>DomainName</th></tr>\n",
              "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
              "</thead>\n",
              "<tbody>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938133070</td><td>Supporting NHS England Initiatives</td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132908</td><td>Antimicrobial Resistance          </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132909</td><td>Antibiotic Prescribing            </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132910</td><td>Health Care Associated Infection  </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132917</td><td>Infection Prevention and Control  </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132929</td><td>Antimicrobial Stewardship         </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132967</td><td>All Trust                         </td></tr>\n",
              "\t<tr><td>101</td><td>AMR local indicators - produced by the UKHSA</td><td>1938132968</td><td>All Clinical Commissioning Group  </td></tr>\n",
              "</tbody>\n",
              "</table>\n"
            ],
            "text/markdown": "\nA tibble: 8 × 4\n\n| ProfileID &lt;int&gt; | ProfileName &lt;chr&gt; | DomainID &lt;int&gt; | DomainName &lt;chr&gt; |\n|---|---|---|---|\n| 101 | AMR local indicators - produced by the UKHSA | 1938133070 | Supporting NHS England Initiatives |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132908 | Antimicrobial Resistance           |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132909 | Antibiotic Prescribing             |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132910 | Health Care Associated Infection   |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132917 | Infection Prevention and Control   |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132929 | Antimicrobial Stewardship          |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132967 | All Trust                          |\n| 101 | AMR local indicators - produced by the UKHSA | 1938132968 | All Clinical Commissioning Group   |\n\n",
            "text/latex": "A tibble: 8 × 4\n\\begin{tabular}{llll}\n ProfileID & ProfileName & DomainID & DomainName\\\\\n <int> & <chr> & <int> & <chr>\\\\\n\\hline\n\t 101 & AMR local indicators - produced by the UKHSA & 1938133070 & Supporting NHS England Initiatives\\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132908 & Antimicrobial Resistance          \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132909 & Antibiotic Prescribing            \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132910 & Health Care Associated Infection  \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132917 & Infection Prevention and Control  \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132929 & Antimicrobial Stewardship         \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132967 & All Trust                         \\\\\n\t 101 & AMR local indicators - produced by the UKHSA & 1938132968 & All Clinical Commissioning Group  \\\\\n\\end{tabular}\n",
            "text/plain": [
              "  ProfileID ProfileName                                  DomainID  \n",
              "1 101       AMR local indicators - produced by the UKHSA 1938133070\n",
              "2 101       AMR local indicators - produced by the UKHSA 1938132908\n",
              "3 101       AMR local indicators - produced by the UKHSA 1938132909\n",
              "4 101       AMR local indicators - produced by the UKHSA 1938132910\n",
              "5 101       AMR local indicators - produced by the UKHSA 1938132917\n",
              "6 101       AMR local indicators - produced by the UKHSA 1938132929\n",
              "7 101       AMR local indicators - produced by the UKHSA 1938132967\n",
              "8 101       AMR local indicators - produced by the UKHSA 1938132968\n",
              "  DomainName                        \n",
              "1 Supporting NHS England Initiatives\n",
              "2 Antimicrobial Resistance          \n",
              "3 Antibiotic Prescribing            \n",
              "4 Health Care Associated Infection  \n",
              "5 Infection Prevention and Control  \n",
              "6 Antimicrobial Stewardship         \n",
              "7 All Trust                         \n",
              "8 All Clinical Commissioning Group  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "amr_metadata <- fingertipsR::indicator_metadata(IndicatorID = amr_ind_id)\n",
        "amr_metadata"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "K3u4qzK3dSPB",
        "outputId": "9f4cb8aa-ea73-4242-9120-14ec1bc64232"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "<table class=\"dataframe\">\n",
              "<caption>A spec_tbl_df: 26 × 32</caption>\n",
              "<thead>\n",
              "\t<tr><th scope=col>IndicatorID</th><th scope=col>Indicator</th><th scope=col>Definition</th><th scope=col>Rationale</th><th scope=col>Data source</th><th scope=col>Indicator source</th><th scope=col>Methodology</th><th scope=col>Standard population/values</th><th scope=col>Confidence interval details</th><th scope=col>Source of numerator</th><th scope=col>⋯</th><th scope=col>Indicator Content</th><th scope=col>Specific rationale</th><th scope=col>Simple Name</th><th scope=col>Simple Definition</th><th scope=col>Impact of COVID-19</th><th scope=col>Unit</th><th scope=col>Value type</th><th scope=col>Year type</th><th scope=col>Polarity</th><th scope=col>Date updated</th></tr>\n",
              "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>⋯</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;lgl&gt;</th><th scope=col>&lt;lgl&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
              "</thead>\n",
              "<tbody>\n",
              "\t<tr><td>92021</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                  </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (from voluntary English laboratory surveillance) with susceptibility tests to a carbapenem; by ICB sub-location and by Quarter (2015 Q1 onwards).The testing ofE. coliblood specimens for carbapenem (meropenem/imipenem/ertapenem) susceptibility is recommended within the Standards for Microbiology Investigations (SMI) https://www.gov.uk/government/publications/smi-b-60-detection-of-bacteria-with-carbapenem-hydrolysing-lactamases-carbapenemases &lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased carbapenem susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a carbapenem (meropenem/imipenem or ertapenem) in each ICB sub-location by quarter, in line with the guidance. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </span></td><td>Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module</td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in initial reportedE. coli positive patient blood specimens in England. Total number of carbapenem (meropenem/imipenem or ertapenem) susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                    </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td><span style=white-space:pre-wrap>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                            </span></td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92411</td><td>Percentage of E. coli blood specimens with susceptibility tests to a 3rd Generation Cephalosporin; by quarter                </td><td>Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime); by ICB sub-location and by Quarter (2015 Q1 onwards). Third Generation Cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </td><td>This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd Generation Cephalosporin by laboratories for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.         </td><td>NA</td><td>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime) susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                        </td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92413</td><td>Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                 </td><td>Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; byICB sub-location and by Quarter (2015 Q1 onwards). Ciprofloxacin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of flouroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </td><td>This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to ciprofloxacin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                        </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92415</td><td>Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                    </td><td>Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by ICB sub-location and by Quarter (2015 Q1 onwards). Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </td><td>This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to gentamicin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </td><td>Routine Laboratory surveillance reports to Public Health England via the second generation surveillance system (SGSS); Antimicrobial testing data module.                 </td><td>NA</td><td>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                           </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92417</td><td>Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                       </td><td>Percentage ofE. coliblood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by CCG and by Quarter (2015 Q1 onwards). Piperacillin/tazobactam resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </td><td>This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility to piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). Testing by CCG has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.         </td><td>NA</td><td>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                              </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92466</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to ciprofloxacin; by quarter                       </td><td>Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of fluoroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </td><td>This indicator demonstrates the rolling average quarterly proportions ofciprofloxacin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility ciprofloxacin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by CCG in England.Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                         </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92518</td><td><span style=white-space:pre-wrap>Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to trimethoprim; by quarter          </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli (or those reported as coliform) urine specimens (GP/Community specimens identifed from voluntary English laboratory surveillance) with susceptibility tests to trimethoprim; by ICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for trimethoprim (a primary UTI treatment option) susceptibility is recommended.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased trimethoprim susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                        </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coli/coliformurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).This indicator is designed to enable community prescribers to assess their first line urinary tract infection therapy in the context of what is identified in local patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </span></td><td>Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module</td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.Total number of trimethoprim susceptibility tests on initial E. coli positive community urine specimens isdivided by the aggregated total of initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                       </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td><span style=white-space:pre-wrap>Voluntary laboratory reports ofEscherichia coli(E. coli) or coliform positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                    </span></td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92519</td><td><span style=white-space:pre-wrap>Percentage of community E. coli (or coliform) urine specimens resistant to trimethoprim; by quarter                          </span></td><td><span style=white-space:pre-wrap>Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) non-susceptible to trimethoprim; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased non-susceptibility to trimethoprim of tested urine specimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location, and are identified as non-susceptible.Non-susceptibility by ICB sub-location has been graded to green (&lt;25% of tested initialE.coliurine isolates identified as non-susceptible), amber (25-49% isolates) and red for those where 50% or more are non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </span></td><td>Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module</td><td>NA</td><td>The percentage of non-susceptible (resistant or intermediate) test results in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England. Total number of trimethoprim non-susceptible test results on initial E. coli positive community urine specimens isdivided by the aggregated total of trimethoprim tested initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Results are suppressed if susceptibility testing in that area over the time period (quarter) is &lt;70%, or if the numerator or denominator are small numbers (&lt;5). A zero value is still presented.</td><td>NA</td><td>No confidence intervals generated for this indicator</td><td><span style=white-space:pre-wrap>Voluntary laboratory reports ofEscherichia coli(E. coli; or coliform) positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                            </span></td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92520</td><td><span style=white-space:pre-wrap>Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to nitrofurantoin; by quarter        </span></td><td><span style=white-space:pre-wrap>Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) with susceptibility tests to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for nitrofurantoin(a primary UTI treatment option) susceptibility is recommended.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased nitrofurantoinsusceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                    </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin by laboratories (and recorded as originating from a community location) for patients in eachICB sub-location.Testing by ICB sub-location has been graded to green (100% of initialE.coliurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).Coliform specimens are included where no further species or genus information is available for that patient specimen - within 2 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </span></td><td>Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module</td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.\r\n",
              "Total number of nitrofurantoin susceptibility tests on initialE. coli positive community urine specimens isdivided by the aggregated total of initialE. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\n",
              "Data are suppressed if the numerator is &lt;5 specimens or the denominator is &lt;5 specimens.                                                                                                                                                        </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td><span style=white-space:pre-wrap>Voluntary laboratory reports ofEscherichia coli(E. coli) positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                </span></td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92521</td><td><span style=white-space:pre-wrap>Percentage of community E. coli (or coliform) urine specimens resistant to nitrofurantoin; by quarter                        </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli (or coliform without further species information) urine specimens (community specimens identifed from voluntary English laboratory surveillance) non-susceptible to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased nitrofurantoin non-susceptibility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin and found resistant (or intermediate) by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Non-susceptibility by ICB sub-location has been graded to green (&lt;25% of initialE.coliurine isolates), amber (25-49% isolates) and red for those where 50% or more have been identified as non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span></td><td>Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module</td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic non-susceptibility in initial reportedE. coli, or specimens reported as ‘coliform’ without further speciation,positive patient community urine specimens in England. Total number of nitrofurantoin non-susceptible community initial E. colipositive community urine specimens isdivided by the aggregated total of nitrofurantoin tested initial E. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Data are suppressed if the numerator is &lt;5 specimens, the denominator is &lt;5 specimens or the proportion tested in the area is &lt;70%.                                                                                             </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td><span style=white-space:pre-wrap>Voluntary laboratory reports ofEscherichia coli(E. coli)or coliform positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                              </span></td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92557</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to gentamicin; by quarter                          </td><td>Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </td><td>This indicator demonstrates the rolling average quarterly proportions ofgentamicin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility gentamicin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                               </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92558</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to piperacillin/tazobactam; by quarter             </td><td>Percentage ofE. coliblood specimens (from English laboratories) with resistant test results (only) for piperacillin/tazobactam (in the first patient specimen); by CCG and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Piperacillin/tazobactam resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactam susceptibility is recommended due to the importance of this combination when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </td><td>This indicator demonstrates the rolling average quarterly proportions ofpiperacillin/tazobactam resistance in initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by CCG has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by CCG in England. Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                              </td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The quarterly average percentage ofresistantantibiotic test results in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactam susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                      </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92559</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to 3rd generation cephalosporins; by quarter       </td><td>Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for 3rd generation cephalosporins (in the first patient specimen); byICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period.3rd generation cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for 3rd generation cephalosporinsusceptibility is recommended due to the importance of 3rd generation cephalosporinswhen treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </td><td>This indicator demonstrates the rolling average quarterly proportions of 3rd generation cephalosporin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd generation cephalosporin (cefoxatime/ceftazidime/cefpodoxime/ceftriaxone) by laboratories for patients in each CICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-locationhas been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of 3rd generation cephalosporin resistance by ICB sub-location in England.Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                    </td><td>Routine laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The quarterly average percentage of resistantantibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd-generation cephalosporin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd-generation cephalosporin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                            </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92602</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to at least 3 of the key antimicrobials; by quarter</td><td>Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for at least three of the 5 key antimicrobials when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen); by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance, including 'multi-drug resistance' inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections.3rd generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime.Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem.                                                                                                                                                                                                          </td><td>This indicator demonstrates the rolling average quarterly proportions ofresistance to 3 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location. These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by CCG in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).               </td><td>Routine Laboratory surveillance reports to UKHSA via the second generation surveillance system (SGSS); Antimicrobial testing data module.                                 </td><td>NA</td><td>The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of test resultson initialE. colipositive blood specimens resistantto 3 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                            </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92603</td><td>Rolling quarterly average proportion of E. coli blood specimens resistant to any 1 of the key antimicrobials; by quarter     </td><td>Percentage ofE. coli blood specimens (from English laboratories) with a resistant test result for any one of the five key antimicrobials, when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen), by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance to any of these antimicrobials inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections. 3rd-generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime. Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem                                                                                                                                                                                                               </td><td>This indicator demonstrates the rolling average quarterly proportions of resistance to any 1 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location.These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making.A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).</td><td>Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         </td><td>NA</td><td>The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England.Total number of test resultson initialE. colipositive blood specimens resistantto any 1 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                          </td><td>NA</td><td>NA                                                  </td><td>Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92665</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                    </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to gentamicin; by acute Trust and by Quarter (2016 Q1 onwards).Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing of blood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.For this indicator, a higher value is indicative of increased gentamicin susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                               </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the quarterly proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\n",
              "If less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    </span></td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. For each quarter: Total number of gentamicin susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                           </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92666</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                  </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to a carbapenem (meropenem, imipenem or ertapenem); by NHS acute Trust and by Quarter (2016 Q1 onwards).\r\n",
              "Carbapenem resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for carbapenem susceptibility is recommended due to the importance ofcarbapenems when treating serious infections.\r\n",
              "For this indicator, a higher value is indicative of increased carbapenem susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                      </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to a carbepenem in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\n",
              "If less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    </span></td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of carbapenem susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of linked initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                          </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92667</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                 </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to ciprofloxacin; by NHS acute Trust and by Quarter (2016 Q1 onwards).Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance offluoroquinolones when treating serious infections.For this indicator, a higher value is indicative of increased ciprofloxacin susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                  </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\n",
              "If less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    </span></td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin susceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                 </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92668</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                       </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to piperacillin/tazobactam; by NHS acute Trust and by Quarter (2016 Q1 onwards).&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased piperacillin/tazobactamsusceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust(mandatory surveillance) that have been tested for susceptibility to piperacillin/tazobactamin each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\n",
              "If less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  </span></td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactamsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                        </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>92669</td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens with susceptibility tests to a 3rd generation cephalosporin; by quarter                </span></td><td><span style=white-space:pre-wrap>Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to 3rd generation cephalosporin (cefotaxime/ceftazidime/cefpodoxime or ceftriaxone); by NHS acute Trust and by Quarter (2016 Q1 onwards).Third generation cephalosporin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporin susceptibility is recommended due to the importance ofcephalosporins when treating serious infections.For this indicator, a higher value is indicative of increased 3rd generation cephalosporin susceptibility testing.The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                      </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to 3rd generation cephalosporins in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\n",
              "If less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  </span></td><td>NA</td><td><span style=white-space:pre-wrap>The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of 3rd generation cephalosporinsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\n",
              "The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.                                                                                                          </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td><span style=white-space:pre-wrap>Not applicable   </span></td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>93037</td><td>Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to azithromycin; by year                              </td><td>All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for azithromycin susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for azithromycin susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </td><td>A summary figure of gonorrhoea cultures tested for azithromycin susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes ceftriaxone and azithromycin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </td><td>Public Health England                                                                                                                                                     </td><td>NA</td><td>Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </td><td>NA</td><td>NA                                                  </td><td>Azithromycin susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                     </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>27/02/2023</td></tr>\n",
              "\t<tr><td>93038</td><td>Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to ceftriaxone; by year                               </td><td>All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for ceftriaxone susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for ceftriaxone susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </td><td>A summary figure of gonorrhoea cultures tested for ceftriaxone susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes azithromycin and ceftriaxone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </td><td>Public Health England                                                                                                                                                     </td><td>NA</td><td>Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </td><td>NA</td><td>NA                                                  </td><td>Ceftriaxone susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                      </td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>Not applicable   </td><td>28/02/2023</td></tr>\n",
              "\t<tr><td>93184</td><td><span style=white-space:pre-wrap>Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens; by quarter                             </span></td><td><span style=white-space:pre-wrap>Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen in specimens linked to mandatory surveillance E. coli bacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forgentamicinsusceptibility is recommended due to the importance ofaminoglycosideswhen treating serious infections.\r\n",
              "For this indicator, a higher value is indicative of increased gentamicin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                        </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                                </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency’s via the second generation surveillance system (SGSS); Antimicrobial testing data module  </span></td><td>NA</td><td><span style=white-space:pre-wrap>Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of gentamicin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                           </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>93186</td><td><span style=white-space:pre-wrap>Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens; by quarter                          </span></td><td><span style=white-space:pre-wrap>Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen in specimens linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forfluoroquinolonesusceptibility is recommended due to the importance ofciprofloxacinwhen treating serious infections.\r\n",
              "For this indicator, a higher value is indicative of increased ciprofloxacin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                              </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                             </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    </span></td><td>NA</td><td><span style=white-space:pre-wrap>Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                     </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>93187</td><td><span style=white-space:pre-wrap>Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens; by quarter                </span></td><td><span style=white-space:pre-wrap>Percentage ofE. coliblood specimens (from English laboratories) with resistant test results forpiperacillin/tazobactam (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.Piperacillin/tazobactamresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactamsusceptibility is recommended due to the importance ofpiperacillin/tazobactamwhen treating serious infections.\r\n",
              "For this indicator, a higher value is indicative of increased piperacillin/tazobactam resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                   </span></td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to piperacillin/tazobactam each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters)then a data quality issue is indicated in the presented value.                                                                                                                                                                                   </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  </span></td><td>NA</td><td><span style=white-space:pre-wrap>Thequarterly averagepercentage ofresistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactam resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactamsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                   </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "\t<tr><td>93188</td><td><span style=white-space:pre-wrap>Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens; by quarter           </span></td><td>Percentage ofE. coliblood specimens (from English laboratories) with resistant test results fora3rd generation cephalosporin (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.3rd generation cephalosporinresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporinsusceptibility is recommended due to the importance of3rd generation cephalosporinswhen treating serious infections.\r\n",
              "The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account, and the most resistant test result retained.For this indicator, a higher value is indicative of increased3rd generation cephalosporin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;</td><td><span style=white-space:pre-wrap>This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to3rd generation cephalosporin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of3rd generation cephalosporin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters) then a data quality issue is indicated in the presented value.                                                                                                                                                                          </span></td><td><span style=white-space:pre-wrap>Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    </span></td><td>NA</td><td><span style=white-space:pre-wrap>Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of3rd generation cephalosporin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd generation cephalosporinsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                         </span></td><td>NA</td><td>No confidence intervals generated for this indicator</td><td>Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.</td><td>⋯</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>%</td><td>Proportion</td><td>Calendar</td><td>RAG - Low is good</td><td>14/03/2024</td></tr>\n",
              "</tbody>\n",
              "</table>\n"
            ],
            "text/markdown": "\nA spec_tbl_df: 26 × 32\n\n| IndicatorID &lt;int&gt; | Indicator &lt;chr&gt; | Definition &lt;chr&gt; | Rationale &lt;chr&gt; | Data source &lt;chr&gt; | Indicator source &lt;chr&gt; | Methodology &lt;chr&gt; | Standard population/values &lt;chr&gt; | Confidence interval details &lt;chr&gt; | Source of numerator &lt;chr&gt; | ⋯ ⋯ | Indicator Content &lt;chr&gt; | Specific rationale &lt;chr&gt; | Simple Name &lt;lgl&gt; | Simple Definition &lt;lgl&gt; | Impact of COVID-19 &lt;chr&gt; | Unit &lt;chr&gt; | Value type &lt;chr&gt; | Year type &lt;chr&gt; | Polarity &lt;chr&gt; | Date updated &lt;chr&gt; |\n|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n| 92021 | Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                   | Percentage of E. coli blood specimens (from voluntary English laboratory surveillance) with susceptibility tests to a carbapenem; by ICB sub-location and by Quarter (2015 Q1 onwards).The testing ofE. coliblood specimens for carbapenem (meropenem/imipenem/ertapenem) susceptibility is recommended within the Standards for Microbiology Investigations (SMI) https://www.gov.uk/government/publications/smi-b-60-detection-of-bacteria-with-carbapenem-hydrolysing-lactamases-carbapenemases &lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased carbapenem susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | This indicator demonstrates the proportion of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a carbapenem (meropenem/imipenem or ertapenem) in each ICB sub-location by quarter, in line with the guidance. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module | NA | The percentage of antibiotic susceptibility tests in initial reportedE. coli positive patient blood specimens in England. Total number of carbapenem (meropenem/imipenem or ertapenem) susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                     | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                             | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92411 | Percentage of E. coli blood specimens with susceptibility tests to a 3rd Generation Cephalosporin; by quarter                 | Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime); by ICB sub-location and by Quarter (2015 Q1 onwards). Third Generation Cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd Generation Cephalosporin by laboratories for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.          | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime) susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                         | NA | No confidence intervals generated for this indicator | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92413 | Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                  | Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; byICB sub-location and by Quarter (2015 Q1 onwards). Ciprofloxacin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of flouroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to ciprofloxacin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                         | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92415 | Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                     | Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by ICB sub-location and by Quarter (2015 Q1 onwards). Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to gentamicin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Routine Laboratory surveillance reports to Public Health England via the second generation surveillance system (SGSS); Antimicrobial testing data module.                  | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                            | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92417 | Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                        | Percentage ofE. coliblood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by CCG and by Quarter (2015 Q1 onwards). Piperacillin/tazobactam resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility to piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). Testing by CCG has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.          | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                               | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92466 | Rolling quarterly average proportion of E. coli blood specimens resistant to ciprofloxacin; by quarter                        | Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of fluoroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | This indicator demonstrates the rolling average quarterly proportions ofciprofloxacin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility ciprofloxacin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by CCG in England.Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                          | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92518 | Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to trimethoprim; by quarter           | Percentage of E. coli (or those reported as coliform) urine specimens (GP/Community specimens identifed from voluntary English laboratory surveillance) with susceptibility tests to trimethoprim; by ICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for trimethoprim (a primary UTI treatment option) susceptibility is recommended.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased trimethoprim susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                         | This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coli/coliformurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).This indicator is designed to enable community prescribers to assess their first line urinary tract infection therapy in the context of what is identified in local patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.Total number of trimethoprim susceptibility tests on initial E. coli positive community urine specimens isdivided by the aggregated total of initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                        | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) or coliform positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                     | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92519 | Percentage of community E. coli (or coliform) urine specimens resistant to trimethoprim; by quarter                           | Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) non-susceptible to trimethoprim; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased non-susceptibility to trimethoprim of tested urine specimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location, and are identified as non-susceptible.Non-susceptibility by ICB sub-location has been graded to green (&lt;25% of tested initialE.coliurine isolates identified as non-susceptible), amber (25-49% isolates) and red for those where 50% or more are non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module | NA | The percentage of non-susceptible (resistant or intermediate) test results in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England. Total number of trimethoprim non-susceptible test results on initial E. coli positive community urine specimens isdivided by the aggregated total of trimethoprim tested initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Results are suppressed if susceptibility testing in that area over the time period (quarter) is &lt;70%, or if the numerator or denominator are small numbers (&lt;5). A zero value is still presented. | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli; or coliform) positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                             | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92520 | Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to nitrofurantoin; by quarter         | Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) with susceptibility tests to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for nitrofurantoin(a primary UTI treatment option) susceptibility is recommended.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased nitrofurantoinsusceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                     | This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin by laboratories (and recorded as originating from a community location) for patients in eachICB sub-location.Testing by ICB sub-location has been graded to green (100% of initialE.coliurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).Coliform specimens are included where no further species or genus information is available for that patient specimen - within 2 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module | NA | The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.\r\nTotal number of nitrofurantoin susceptibility tests on initialE. coli positive community urine specimens isdivided by the aggregated total of initialE. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\nData are suppressed if the numerator is &lt;5 specimens or the denominator is &lt;5 specimens.                                                                                                                                                         | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                 | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92521 | Percentage of community E. coli (or coliform) urine specimens resistant to nitrofurantoin; by quarter                         | Percentage of E. coli (or coliform without further species information) urine specimens (community specimens identifed from voluntary English laboratory surveillance) non-susceptible to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased nitrofurantoin non-susceptibility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin and found resistant (or intermediate) by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Non-susceptibility by ICB sub-location has been graded to green (&lt;25% of initialE.coliurine isolates), amber (25-49% isolates) and red for those where 50% or more have been identified as non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module | NA | The percentage of antibiotic non-susceptibility in initial reportedE. coli, or specimens reported as ‘coliform’ without further speciation,positive patient community urine specimens in England. Total number of nitrofurantoin non-susceptible community initial E. colipositive community urine specimens isdivided by the aggregated total of nitrofurantoin tested initial E. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Data are suppressed if the numerator is &lt;5 specimens, the denominator is &lt;5 specimens or the proportion tested in the area is &lt;70%.                                                                                              | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli)or coliform positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                               | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92557 | Rolling quarterly average proportion of E. coli blood specimens resistant to gentamicin; by quarter                           | Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | This indicator demonstrates the rolling average quarterly proportions ofgentamicin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility gentamicin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92558 | Rolling quarterly average proportion of E. coli blood specimens resistant to piperacillin/tazobactam; by quarter              | Percentage ofE. coliblood specimens (from English laboratories) with resistant test results (only) for piperacillin/tazobactam (in the first patient specimen); by CCG and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Piperacillin/tazobactam resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactam susceptibility is recommended due to the importance of this combination when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | This indicator demonstrates the rolling average quarterly proportions ofpiperacillin/tazobactam resistance in initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by CCG has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by CCG in England. Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The quarterly average percentage ofresistantantibiotic test results in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactam susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                       | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92559 | Rolling quarterly average proportion of E. coli blood specimens resistant to 3rd generation cephalosporins; by quarter        | Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for 3rd generation cephalosporins (in the first patient specimen); byICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period.3rd generation cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for 3rd generation cephalosporinsusceptibility is recommended due to the importance of 3rd generation cephalosporinswhen treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | This indicator demonstrates the rolling average quarterly proportions of 3rd generation cephalosporin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd generation cephalosporin (cefoxatime/ceftazidime/cefpodoxime/ceftriaxone) by laboratories for patients in each CICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-locationhas been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of 3rd generation cephalosporin resistance by ICB sub-location in England.Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                     | Routine laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The quarterly average percentage of resistantantibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd-generation cephalosporin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd-generation cephalosporin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                             | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92602 | Rolling quarterly average proportion of E. coli blood specimens resistant to at least 3 of the key antimicrobials; by quarter | Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for at least three of the 5 key antimicrobials when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen); by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance, including 'multi-drug resistance' inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections.3rd generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime.Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem.                                                                                                                                                                                                           | This indicator demonstrates the rolling average quarterly proportions ofresistance to 3 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location. These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by CCG in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                | Routine Laboratory surveillance reports to UKHSA via the second generation surveillance system (SGSS); Antimicrobial testing data module.                                  | NA | The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of test resultson initialE. colipositive blood specimens resistantto 3 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                             | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92603 | Rolling quarterly average proportion of E. coli blood specimens resistant to any 1 of the key antimicrobials; by quarter      | Percentage ofE. coli blood specimens (from English laboratories) with a resistant test result for any one of the five key antimicrobials, when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen), by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance to any of these antimicrobials inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections. 3rd-generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime. Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem                                                                                                                                                                                                                | This indicator demonstrates the rolling average quarterly proportions of resistance to any 1 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location.These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making.A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014). | Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          | NA | The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England.Total number of test resultson initialE. colipositive blood specimens resistantto any 1 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                           | NA | NA                                                   | Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 92665 | Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                     | Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to gentamicin; by acute Trust and by Quarter (2016 Q1 onwards).Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing of blood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.For this indicator, a higher value is indicative of increased gentamicin susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                | This indicator demonstrates the quarterly proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     | NA | The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. For each quarter: Total number of gentamicin susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                            | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92666 | Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                   | Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to a carbapenem (meropenem, imipenem or ertapenem); by NHS acute Trust and by Quarter (2016 Q1 onwards).\r\nCarbapenem resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for carbapenem susceptibility is recommended due to the importance ofcarbapenems when treating serious infections.\r\nFor this indicator, a higher value is indicative of increased carbapenem susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                       | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to a carbepenem in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     | NA | The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of carbapenem susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of linked initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                           | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92667 | Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                  | Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to ciprofloxacin; by NHS acute Trust and by Quarter (2016 Q1 onwards).Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance offluoroquinolones when treating serious infections.For this indicator, a higher value is indicative of increased ciprofloxacin susceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                   | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     | NA | The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin susceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                  | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92668 | Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                        | Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to piperacillin/tazobactam; by NHS acute Trust and by Quarter (2016 Q1 onwards).&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;For this indicator, a higher value is indicative of increased piperacillin/tazobactamsusceptibility testing.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust(mandatory surveillance) that have been tested for susceptibility to piperacillin/tazobactamin each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   | NA | The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactamsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                         | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 92669 | Percentage of E. coli blood specimens with susceptibility tests to a 3rd generation cephalosporin; by quarter                 | Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to 3rd generation cephalosporin (cefotaxime/ceftazidime/cefpodoxime or ceftriaxone); by NHS acute Trust and by Quarter (2016 Q1 onwards).Third generation cephalosporin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporin susceptibility is recommended due to the importance ofcephalosporins when treating serious infections.For this indicator, a higher value is indicative of increased 3rd generation cephalosporin susceptibility testing.The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                       | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to 3rd generation cephalosporins in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\r\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   | NA | The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of 3rd generation cephalosporinsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.                                                                                                           | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 14/03/2024 |\n| 93037 | Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to azithromycin; by year                               | All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for azithromycin susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for azithromycin susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | A summary figure of gonorrhoea cultures tested for azithromycin susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes ceftriaxone and azithromycin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Public Health England                                                                                                                                                      | NA | Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NA | NA                                                   | Azithromycin susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                      | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 27/02/2023 |\n| 93038 | Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to ceftriaxone; by year                                | All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for ceftriaxone susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for ceftriaxone susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | A summary figure of gonorrhoea cultures tested for ceftriaxone susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes azithromycin and ceftriaxone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Public Health England                                                                                                                                                      | NA | Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NA | NA                                                   | Ceftriaxone susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                       | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | Not applicable    | 28/02/2023 |\n| 93184 | Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens; by quarter                              | Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen in specimens linked to mandatory surveillance E. coli bacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forgentamicinsusceptibility is recommended due to the importance ofaminoglycosideswhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased gentamicin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                                         | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                                 | Routine voluntary laboratory surveillance reports to UK Health Security Agency’s via the second generation surveillance system (SGSS); Antimicrobial testing data module   | NA | Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of gentamicin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                            | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 93186 | Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens; by quarter                           | Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen in specimens linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forfluoroquinolonesusceptibility is recommended due to the importance ofciprofloxacinwhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased ciprofloxacin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                                                                               | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                              | Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     | NA | Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                      | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 93187 | Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens; by quarter                 | Percentage ofE. coliblood specimens (from English laboratories) with resistant test results forpiperacillin/tazobactam (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.Piperacillin/tazobactamresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactamsusceptibility is recommended due to the importance ofpiperacillin/tazobactamwhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased piperacillin/tazobactam resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt;                                                                                                                                                                                                                                                    | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to piperacillin/tazobactam each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters)then a data quality issue is indicated in the presented value.                                                                                                                                                                                    | Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   | NA | Thequarterly averagepercentage ofresistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactam resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactamsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                    | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n| 93188 | Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens; by quarter            | Percentage ofE. coliblood specimens (from English laboratories) with resistant test results fora3rd generation cephalosporin (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.3rd generation cephalosporinresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporinsusceptibility is recommended due to the importance of3rd generation cephalosporinswhen treating serious infections.\r\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account, and the most resistant test result retained.For this indicator, a higher value is indicative of increased3rd generation cephalosporin resistance.&lt;a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\"&gt; | This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to3rd generation cephalosporin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of3rd generation cephalosporin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters) then a data quality issue is indicated in the presented value.                                                                                                                                                                           | Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     | NA | Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of3rd generation cephalosporin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd generation cephalosporinsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                          | NA | No confidence intervals generated for this indicator | Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. | ⋯ | NA | NA | NA | NA | NA | % | Proportion | Calendar | RAG - Low is good | 14/03/2024 |\n\n",
            "text/latex": "A spec\\_tbl\\_df: 26 × 32\n\\begin{tabular}{lllllllllllllllllllll}\n IndicatorID & Indicator & Definition & Rationale & Data source & Indicator source & Methodology & Standard population/values & Confidence interval details & Source of numerator & ⋯ & Indicator Content & Specific rationale & Simple Name & Simple Definition & Impact of COVID-19 & Unit & Value type & Year type & Polarity & Date updated\\\\\n <int> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & ⋯ & <chr> & <chr> & <lgl> & <lgl> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n\\hline\n\t 92021 & Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                   & Percentage of E. coli blood specimens (from voluntary English laboratory surveillance) with susceptibility tests to a carbapenem; by ICB sub-location and by Quarter (2015 Q1 onwards).The testing ofE. coliblood specimens for carbapenem (meropenem/imipenem/ertapenem) susceptibility is recommended within the Standards for Microbiology Investigations (SMI) https://www.gov.uk/government/publications/smi-b-60-detection-of-bacteria-with-carbapenem-hydrolysing-lactamases-carbapenemases <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">For this indicator, a higher value is indicative of increased carbapenem susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & This indicator demonstrates the proportion of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a carbapenem (meropenem/imipenem or ertapenem) in each ICB sub-location by quarter, in line with the guidance. Testing by ICB sub-location has been graded to green (100\\% of initial E.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               & Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module & NA & The percentage of antibiotic susceptibility tests in initial reportedE. coli positive patient blood specimens in England. Total number of carbapenem (meropenem/imipenem or ertapenem) susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                     & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                             & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92411 & Percentage of E. coli blood specimens with susceptibility tests to a 3rd Generation Cephalosporin; by quarter                 & Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime); by ICB sub-location and by Quarter (2015 Q1 onwards). Third Generation Cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   & This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd Generation Cephalosporin by laboratories for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100\\% of initial E.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.          & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime) susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                         & NA & No confidence intervals generated for this indicator & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92413 & Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                  & Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; byICB sub-location and by Quarter (2015 Q1 onwards). Ciprofloxacin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of flouroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             & This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to ciprofloxacin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                         & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92415 & Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                     & Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by ICB sub-location and by Quarter (2015 Q1 onwards). Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     & This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to gentamicin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100\\% of initial E.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  & Routine Laboratory surveillance reports to Public Health England via the second generation surveillance system (SGSS); Antimicrobial testing data module.                  & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                            & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92417 & Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                        & Percentage ofE. coliblood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by CCG and by Quarter (2015 Q1 onwards). Piperacillin/tazobactam resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                & This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility to piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). Testing by CCG has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.          & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                               & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92466 & Rolling quarterly average proportion of E. coli blood specimens resistant to ciprofloxacin; by quarter                        & Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of fluoroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       & This indicator demonstrates the rolling average quarterly proportions ofciprofloxacin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility ciprofloxacin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by CCG in England.Those where less than 70\\% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                          & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92518 & Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to trimethoprim; by quarter           & Percentage of E. coli (or those reported as coliform) urine specimens (GP/Community specimens identifed from voluntary English laboratory surveillance) with susceptibility tests to trimethoprim; by ICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for trimethoprim (a primary UTI treatment option) susceptibility is recommended.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">For this indicator, a higher value is indicative of increased trimethoprim susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                         & This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100\\% of initial E.coli/coliformurine isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).This indicator is designed to enable community prescribers to assess their first line urinary tract infection therapy in the context of what is identified in local patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        & Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.Total number of trimethoprim susceptibility tests on initial E. coli positive community urine specimens isdivided by the aggregated total of initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                        & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) or coliform positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                     & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92519 & Percentage of community E. coli (or coliform) urine specimens resistant to trimethoprim; by quarter                           & Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) non-susceptible to trimethoprim; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased non-susceptibility to trimethoprim of tested urine specimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      & This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location, and are identified as non-susceptible.Non-susceptibility by ICB sub-location has been graded to green (<25\\% of tested initialE.coliurine isolates identified as non-susceptible), amber (25-49\\% isolates) and red for those where 50\\% or more are non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        & Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module & NA & The percentage of non-susceptible (resistant or intermediate) test results in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England. Total number of trimethoprim non-susceptible test results on initial E. coli positive community urine specimens isdivided by the aggregated total of trimethoprim tested initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Results are suppressed if susceptibility testing in that area over the time period (quarter) is <70\\%, or if the numerator or denominator are small numbers (<5). A zero value is still presented. & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli; or coliform) positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                             & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92520 & Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to nitrofurantoin; by quarter         & Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) with susceptibility tests to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for nitrofurantoin(a primary UTI treatment option) susceptibility is recommended.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">For this indicator, a higher value is indicative of increased nitrofurantoinsusceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                     & This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin by laboratories (and recorded as originating from a community location) for patients in eachICB sub-location.Testing by ICB sub-location has been graded to green (100\\% of initialE.coliurine isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested (70\\% cut off used within the ESPAUR report 2014).Coliform specimens are included where no further species or genus information is available for that patient specimen - within 2 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      & Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module & NA & The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.\r\nTotal number of nitrofurantoin susceptibility tests on initialE. coli positive community urine specimens isdivided by the aggregated total of initialE. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\nData are suppressed if the numerator is <5 specimens or the denominator is <5 specimens.                                                                                                                                                         & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                 & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92521 & Percentage of community E. coli (or coliform) urine specimens resistant to nitrofurantoin; by quarter                         & Percentage of E. coli (or coliform without further species information) urine specimens (community specimens identifed from voluntary English laboratory surveillance) non-susceptible to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased nitrofurantoin non-susceptibility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin and found resistant (or intermediate) by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Non-susceptibility by ICB sub-location has been graded to green (<25\\% of initialE.coliurine isolates), amber (25-49\\% isolates) and red for those where 50\\% or more have been identified as non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     & Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module & NA & The percentage of antibiotic non-susceptibility in initial reportedE. coli, or specimens reported as ‘coliform’ without further speciation,positive patient community urine specimens in England. Total number of nitrofurantoin non-susceptible community initial E. colipositive community urine specimens isdivided by the aggregated total of nitrofurantoin tested initial E. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Data are suppressed if the numerator is <5 specimens, the denominator is <5 specimens or the proportion tested in the area is <70\\%.                                                                                              & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli)or coliform positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                               & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92557 & Rolling quarterly average proportion of E. coli blood specimens resistant to gentamicin; by quarter                           & Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & This indicator demonstrates the rolling average quarterly proportions ofgentamicin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility gentamicin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by ICB sub-location in England. Those where less than 70\\% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92558 & Rolling quarterly average proportion of E. coli blood specimens resistant to piperacillin/tazobactam; by quarter              & Percentage ofE. coliblood specimens (from English laboratories) with resistant test results (only) for piperacillin/tazobactam (in the first patient specimen); by CCG and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Piperacillin/tazobactam resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactam susceptibility is recommended due to the importance of this combination when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                & This indicator demonstrates the rolling average quarterly proportions ofpiperacillin/tazobactam resistance in initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by CCG has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by CCG in England. Those where less than 70\\% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                               & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The quarterly average percentage ofresistantantibiotic test results in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactam susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                       & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92559 & Rolling quarterly average proportion of E. coli blood specimens resistant to 3rd generation cephalosporins; by quarter        & Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for 3rd generation cephalosporins (in the first patient specimen); byICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period.3rd generation cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for 3rd generation cephalosporinsusceptibility is recommended due to the importance of 3rd generation cephalosporinswhen treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              & This indicator demonstrates the rolling average quarterly proportions of 3rd generation cephalosporin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd generation cephalosporin (cefoxatime/ceftazidime/cefpodoxime/ceftriaxone) by laboratories for patients in each CICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-locationhas been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of 3rd generation cephalosporin resistance by ICB sub-location in England.Those where less than 70\\% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                     & Routine laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The quarterly average percentage of resistantantibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd-generation cephalosporin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd-generation cephalosporin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                             & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92602 & Rolling quarterly average proportion of E. coli blood specimens resistant to at least 3 of the key antimicrobials; by quarter & Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for at least three of the 5 key antimicrobials when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen); by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance, including 'multi-drug resistance' inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections.3rd generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime.Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem.                                                                                                                                                                                                           & This indicator demonstrates the rolling average quarterly proportions ofresistance to 3 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location. These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by CCG in England. Those where less than 70\\% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).                & Routine Laboratory surveillance reports to UKHSA via the second generation surveillance system (SGSS); Antimicrobial testing data module.                                  & NA & The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of test resultson initialE. colipositive blood specimens resistantto 3 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                             & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92603 & Rolling quarterly average proportion of E. coli blood specimens resistant to any 1 of the key antimicrobials; by quarter      & Percentage ofE. coli blood specimens (from English laboratories) with a resistant test result for any one of the five key antimicrobials, when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen), by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance to any of these antimicrobials inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections. 3rd-generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime. Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem                                                                                                                                                                                                                & This indicator demonstrates the rolling average quarterly proportions of resistance to any 1 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location.These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making.A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by ICB sub-location in England. Those where less than 70\\% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014). & Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.          & NA & The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England.Total number of test resultson initialE. colipositive blood specimens resistantto any 1 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                           & NA & NA                                                   & Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                    & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 92665 & Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                     & Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to gentamicin; by acute Trust and by Quarter (2016 Q1 onwards).Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing of blood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.For this indicator, a higher value is indicative of increased gentamicin susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                                & This indicator demonstrates the quarterly proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested.\r\nIf less than 70\\% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     & Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     & NA & The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. For each quarter: Total number of gentamicin susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                            & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92666 & Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                   & Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to a carbapenem (meropenem, imipenem or ertapenem); by NHS acute Trust and by Quarter (2016 Q1 onwards).\r\nCarbapenem resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for carbapenem susceptibility is recommended due to the importance ofcarbapenems when treating serious infections.\r\nFor this indicator, a higher value is indicative of increased carbapenem susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                       & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to a carbepenem in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested.\r\nIf less than 70\\% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             & Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     & NA & The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of carbapenem susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of linked initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                           & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92667 & Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                  & Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to ciprofloxacin; by NHS acute Trust and by Quarter (2016 Q1 onwards).Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance offluoroquinolones when treating serious infections.For this indicator, a higher value is indicative of increased ciprofloxacin susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                   & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested.\r\nIf less than 70\\% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     & NA & The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin susceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                  & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92668 & Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                        & Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to piperacillin/tazobactam; by NHS acute Trust and by Quarter (2016 Q1 onwards).<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">For this indicator, a higher value is indicative of increased piperacillin/tazobactamsusceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust(mandatory surveillance) that have been tested for susceptibility to piperacillin/tazobactamin each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested.\r\nIf less than 70\\% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   & Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   & NA & The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactamsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                         & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 92669 & Percentage of E. coli blood specimens with susceptibility tests to a 3rd generation cephalosporin; by quarter                 & Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to 3rd generation cephalosporin (cefotaxime/ceftazidime/cefpodoxime or ceftriaxone); by NHS acute Trust and by Quarter (2016 Q1 onwards).Third generation cephalosporin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporin susceptibility is recommended due to the importance ofcephalosporins when treating serious infections.For this indicator, a higher value is indicative of increased 3rd generation cephalosporin susceptibility testing.The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                       & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to 3rd generation cephalosporins in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100\\% of initialE.coliblood isolates), amber (70-99\\% isolates) and red for those where less than 70\\% have been tested.\r\nIf less than 70\\% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 & Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   & NA & The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of 3rd generation cephalosporinsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\r\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.                                                                                                           & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 14/03/2024\\\\\n\t 93037 & Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to azithromycin; by year                               & All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for azithromycin susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for azithromycin susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         & A summary figure of gonorrhoea cultures tested for azithromycin susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes ceftriaxone and azithromycin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     & Public Health England                                                                                                                                                      & NA & Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             & NA & NA                                                   & Azithromycin susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                      & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 27/02/2023\\\\\n\t 93038 & Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to ceftriaxone; by year                                & All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for ceftriaxone susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for ceftriaxone susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           & A summary figure of gonorrhoea cultures tested for ceftriaxone susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes azithromycin and ceftriaxone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      & Public Health England                                                                                                                                                      & NA & Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             & NA & NA                                                   & Ceftriaxone susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                       & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & Not applicable    & 28/02/2023\\\\\n\t 93184 & Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens; by quarter                              & Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen in specimens linked to mandatory surveillance E. coli bacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forgentamicinsusceptibility is recommended due to the importance ofaminoglycosideswhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased gentamicin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                         & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by acute Trust in England.Those where less than 70\\% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).If less than 70\\% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                                 & Routine voluntary laboratory surveillance reports to UK Health Security Agency’s via the second generation surveillance system (SGSS); Antimicrobial testing data module   & NA & Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of gentamicin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                            & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 93186 & Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens; by quarter                           & Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen in specimens linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forfluoroquinolonesusceptibility is recommended due to the importance ofciprofloxacinwhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased ciprofloxacin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                               & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by acute Trust in England.Those where less than 70\\% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).If less than 70\\% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                              & Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     & NA & Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                      & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 93187 & Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens; by quarter                 & Percentage ofE. coliblood specimens (from English laboratories) with resistant test results forpiperacillin/tazobactam (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.Piperacillin/tazobactamresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactamsusceptibility is recommended due to the importance ofpiperacillin/tazobactamwhen treating serious infections.\r\nFor this indicator, a higher value is indicative of increased piperacillin/tazobactam resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\">                                                                                                                                                                                                                                                    & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to piperacillin/tazobactam each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by acute Trust in England.Those where less than 70\\% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).If less than 70\\% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters)then a data quality issue is indicated in the presented value.                                                                                                                                                                                    & Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module   & NA & Thequarterly averagepercentage ofresistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactam resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactamsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                    & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\t 93188 & Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens; by quarter            & Percentage ofE. coliblood specimens (from English laboratories) with resistant test results fora3rd generation cephalosporin (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.3rd generation cephalosporinresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporinsusceptibility is recommended due to the importance of3rd generation cephalosporinswhen treating serious infections.\r\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account, and the most resistant test result retained.For this indicator, a higher value is indicative of increased3rd generation cephalosporin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/344071/P\\_8i1.1.pdf\"> & This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to3rd generation cephalosporin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of3rd generation cephalosporin resistance by acute Trust in England.Those where less than 70\\% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70\\% is the cut off used within the ESPAUR report 2014).If less than 70\\% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters) then a data quality issue is indicated in the presented value.                                                                                                                                                                           & Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module     & NA & Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of3rd generation cephalosporin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd generation cephalosporinsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                          & NA & No confidence intervals generated for this indicator & Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia. & ⋯ & NA & NA & NA & NA & NA & \\% & Proportion & Calendar & RAG - Low is good & 14/03/2024\\\\\n\\end{tabular}\n",
            "text/plain": [
              "   IndicatorID\n",
              "1  92021      \n",
              "2  92411      \n",
              "3  92413      \n",
              "4  92415      \n",
              "5  92417      \n",
              "6  92466      \n",
              "7  92518      \n",
              "8  92519      \n",
              "9  92520      \n",
              "10 92521      \n",
              "11 92557      \n",
              "12 92558      \n",
              "13 92559      \n",
              "14 92602      \n",
              "15 92603      \n",
              "16 92665      \n",
              "17 92666      \n",
              "18 92667      \n",
              "19 92668      \n",
              "20 92669      \n",
              "21 93037      \n",
              "22 93038      \n",
              "23 93184      \n",
              "24 93186      \n",
              "25 93187      \n",
              "26 93188      \n",
              "   Indicator                                                                                                                    \n",
              "1  Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                  \n",
              "2  Percentage of E. coli blood specimens with susceptibility tests to a 3rd Generation Cephalosporin; by quarter                \n",
              "3  Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                 \n",
              "4  Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                    \n",
              "5  Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                       \n",
              "6  Rolling quarterly average proportion of E. coli blood specimens resistant to ciprofloxacin; by quarter                       \n",
              "7  Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to trimethoprim; by quarter          \n",
              "8  Percentage of community E. coli (or coliform) urine specimens resistant to trimethoprim; by quarter                          \n",
              "9  Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to nitrofurantoin; by quarter        \n",
              "10 Percentage of community E. coli (or coliform) urine specimens resistant to nitrofurantoin; by quarter                        \n",
              "11 Rolling quarterly average proportion of E. coli blood specimens resistant to gentamicin; by quarter                          \n",
              "12 Rolling quarterly average proportion of E. coli blood specimens resistant to piperacillin/tazobactam; by quarter             \n",
              "13 Rolling quarterly average proportion of E. coli blood specimens resistant to 3rd generation cephalosporins; by quarter       \n",
              "14 Rolling quarterly average proportion of E. coli blood specimens resistant to at least 3 of the key antimicrobials; by quarter\n",
              "15 Rolling quarterly average proportion of E. coli blood specimens resistant to any 1 of the key antimicrobials; by quarter     \n",
              "16 Percentage of E. coli blood specimens with susceptibility tests to gentamicin; by quarter                                    \n",
              "17 Percentage of E. coli blood specimens with susceptibility tests to a carbapenem; by quarter                                  \n",
              "18 Percentage of E. coli blood specimens with susceptibility tests to ciprofloxacin; by quarter                                 \n",
              "19 Percentage of E. coli blood specimens with susceptibility tests to piperacillin/tazobactam; by quarter                       \n",
              "20 Percentage of E. coli blood specimens with susceptibility tests to a 3rd generation cephalosporin; by quarter                \n",
              "21 Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to azithromycin; by year                              \n",
              "22 Percentage of Neisseria gonorrhoeae isolates with susceptibility tests to ceftriaxone; by year                               \n",
              "23 Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens; by quarter                             \n",
              "24 Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens; by quarter                          \n",
              "25 Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens; by quarter                \n",
              "26 Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens; by quarter           \n",
              "   Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "1  Percentage of E. coli blood specimens (from voluntary English laboratory surveillance) with susceptibility tests to a carbapenem; by ICB sub-location and by Quarter (2015 Q1 onwards).The testing ofE. coliblood specimens for carbapenem (meropenem/imipenem/ertapenem) susceptibility is recommended within the Standards for Microbiology Investigations (SMI) https://www.gov.uk/government/publications/smi-b-60-detection-of-bacteria-with-carbapenem-hydrolysing-lactamases-carbapenemases <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">For this indicator, a higher value is indicative of increased carbapenem susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "2  Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime); by ICB sub-location and by Quarter (2015 Q1 onwards). Third Generation Cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
              "3  Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; byICB sub-location and by Quarter (2015 Q1 onwards). Ciprofloxacin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of flouroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \n",
              "4  Percentage ofE. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by ICB sub-location and by Quarter (2015 Q1 onwards). Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
              "5  Percentage ofE. coliblood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by CCG and by Quarter (2015 Q1 onwards). Piperacillin/tazobactam resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
              "6  Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance of fluoroquinolones when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \n",
              "7  Percentage of E. coli (or those reported as coliform) urine specimens (GP/Community specimens identifed from voluntary English laboratory surveillance) with susceptibility tests to trimethoprim; by ICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for trimethoprim (a primary UTI treatment option) susceptibility is recommended.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">For this indicator, a higher value is indicative of increased trimethoprim susceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                        \n",
              "8  Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) non-susceptible to trimethoprim; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased non-susceptibility to trimethoprim of tested urine specimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \n",
              "9  Percentage of communityE. coli (or coliform without further speciation) urine specimens (from voluntary English laboratory surveillance) with susceptibility tests to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.The testing ofE. coliurine specimens for nitrofurantoin(a primary UTI treatment option) susceptibility is recommended.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">For this indicator, a higher value is indicative of increased nitrofurantoinsusceptibility testing.                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
              "10 Percentage of E. coli (or coliform without further species information) urine specimens (community specimens identifed from voluntary English laboratory surveillance) non-susceptible to nitrofurantoin; byICB sub-location and by Quarter (2015 Q1 onwards).In this context community specimens are those recorded by the laboratory as not being taken in an acute trust setting but rather referred from another source, these include (but not exclusively) GP specimens, community hospital specimens and Care Home urine specimens.For this indicator, a higher value is indicative of increased nitrofurantoin non-susceptibility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "11 Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen); by ICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "12 Percentage ofE. coliblood specimens (from English laboratories) with resistant test results (only) for piperacillin/tazobactam (in the first patient specimen); by CCG and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period. Piperacillin/tazobactam resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactam susceptibility is recommended due to the importance of this combination when treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
              "13 Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for 3rd generation cephalosporins (in the first patient specimen); byICB sub-location and by Quarter (2015 Q4 onwards). Presented as a rolling quarterly average across a 4 quarter period.3rd generation cephalosporin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for 3rd generation cephalosporinsusceptibility is recommended due to the importance of 3rd generation cephalosporinswhen treating serious infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \n",
              "14 Percentage ofE. coli blood specimens (from English laboratories) with resistant test results for at least three of the 5 key antimicrobials when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen); by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance, including 'multi-drug resistance' inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections.3rd generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime.Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem.                                                                                                                                                                                                          \n",
              "15 Percentage ofE. coli blood specimens (from English laboratories) with a resistant test result for any one of the five key antimicrobials, when tested for all 5 antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cepahalosporins, carbapenems; in the first patient specimen), by ICB sub-location and by Quarter (2015 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period (2015 Q4 onwards). Resistance to any of these antimicrobials inE. coliis a key issue as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for susceptibility in all five of the key antimicrobials/classes is recommended due to the importance of this combination when treating serious infections. 3rd-generation cephalospirins in this context are at least one of cefotaxime, ceftazidime, ceftriaxone or cefpodoxime. Carbapenems in this context are imipenem or meropenem and where neither are tested, ertapenem                                                                                                                                                                                                               \n",
              "16 Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to gentamicin; by acute Trust and by Quarter (2016 Q1 onwards).Gentamicin resistance in E. coli is a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing of blood specimens for gentamicin susceptibility is recommended due to the importance of aminoglycosides when treating serious infections.For this indicator, a higher value is indicative of increased gentamicin susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
              "17 Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to a carbapenem (meropenem, imipenem or ertapenem); by NHS acute Trust and by Quarter (2016 Q1 onwards).\\r\\nCarbapenem resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for carbapenem susceptibility is recommended due to the importance ofcarbapenems when treating serious infections.\\r\\nFor this indicator, a higher value is indicative of increased carbapenem susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                      \n",
              "18 Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to ciprofloxacin; by NHS acute Trust and by Quarter (2016 Q1 onwards).Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for ciprofloxacin susceptibility is recommended due to the importance offluoroquinolones when treating serious infections.For this indicator, a higher value is indicative of increased ciprofloxacin susceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
              "19 Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to piperacillin/tazobactam; by NHS acute Trust and by Quarter (2016 Q1 onwards).<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">For this indicator, a higher value is indicative of increased piperacillin/tazobactamsusceptibility testing.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \n",
              "20 Percentage of E. coli blood specimens (reported via UKHSA's voluntary English laboratory surveillance and linked to a mandatory surveillance Trust reported episode) with susceptibility tests to 3rd generation cephalosporin (cefotaxime/ceftazidime/cefpodoxime or ceftriaxone); by NHS acute Trust and by Quarter (2016 Q1 onwards).Third generation cephalosporin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporin susceptibility is recommended due to the importance ofcephalosporins when treating serious infections.For this indicator, a higher value is indicative of increased 3rd generation cephalosporin susceptibility testing.The 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                      \n",
              "21 All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for azithromycin susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for azithromycin susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \n",
              "22 All laboratory confirmed gonorrhoea diagnoses with a culture that are tested for ceftriaxone susceptibility. Data are expressed as a percentage and represent cultured gonorrhoea diagnoses tested for ceftriaxone susceptibility by primary diagnostic laboratories in England.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n",
              "23 Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for gentamicin (in the first patient specimen in specimens linked to mandatory surveillance E. coli bacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Gentamicin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forgentamicinsusceptibility is recommended due to the importance ofaminoglycosideswhen treating serious infections.\\r\\nFor this indicator, a higher value is indicative of increased gentamicin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                                        \n",
              "24 Percentage ofE. coliblood specimens (from English laboratories) with resistant test results for ciprofloxacin (in the first patient specimen in specimens linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period. The first quarter presented is Q4 2016, the quarterly average across 2016.Ciprofloxacin resistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens forfluoroquinolonesusceptibility is recommended due to the importance ofciprofloxacinwhen treating serious infections.\\r\\nFor this indicator, a higher value is indicative of increased ciprofloxacin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                                                                              \n",
              "25 Percentage ofE. coliblood specimens (from English laboratories) with resistant test results forpiperacillin/tazobactam (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.Piperacillin/tazobactamresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for piperacillin/tazobactamsusceptibility is recommended due to the importance ofpiperacillin/tazobactamwhen treating serious infections.\\r\\nFor this indicator, a higher value is indicative of increased piperacillin/tazobactam resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">                                                                                                                                                                                                                                                   \n",
              "26 Percentage ofE. coliblood specimens (from English laboratories) with resistant test results fora3rd generation cephalosporin (in the first patient specimen in specimens successfully linked to mandatory surveillanceE. colibacteraemia reports);by acute Trust and by Quarter (2016 Q1 onwards). Presented as a rolling quarterly average across a 4 quarter period.The first quarter presented is Q4 2016, the quarterly average across 2016.3rd generation cephalosporinresistance inE. coliis a key combination highlighted as part of the government 5-year antimicrobial resistance strategy and as such is recommended for monitoring. The testing ofblood specimens for3rd generation cephalosporinsusceptibility is recommended due to the importance of3rd generation cephalosporinswhen treating serious infections.\\r\\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account, and the most resistant test result retained.For this indicator, a higher value is indicative of increased3rd generation cephalosporin resistance.<a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf\">\n",
              "   Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "1  This indicator demonstrates the proportion of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a carbapenem (meropenem/imipenem or ertapenem) in each ICB sub-location by quarter, in line with the guidance. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \n",
              "2  This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd Generation Cephalosporin by laboratories for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \n",
              "3  This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to ciprofloxacin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
              "4  This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to gentamicin by laboratories for patients in eachICB sub-location. Testing by ICB sub-location has been graded to green (100% of initial E.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \n",
              "5  This indicator demonstrates the quarterly proportions of initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility to piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). Testing by CCG has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "6  This indicator demonstrates the rolling average quarterly proportions ofciprofloxacin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility ciprofloxacin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by CCG in England.Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \n",
              "7  This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Testing by ICB sub-location has been graded to green (100% of initial E.coli/coliformurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).This indicator is designed to enable community prescribers to assess their first line urinary tract infection therapy in the context of what is identified in local patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \n",
              "8  This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli/coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to trimethoprim by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location, and are identified as non-susceptible.Non-susceptibility by ICB sub-location has been graded to green (<25% of tested initialE.coliurine isolates identified as non-susceptible), amber (25-49% isolates) and red for those where 50% or more are non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \n",
              "9  This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin by laboratories (and recorded as originating from a community location) for patients in eachICB sub-location.Testing by ICB sub-location has been graded to green (100% of initialE.coliurine isolates), amber (70-99% isolates) and red for those where less than 70% have been tested (70% cut off used within the ESPAUR report 2014).Coliform specimens are included where no further species or genus information is available for that patient specimen - within 2 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \n",
              "10 This indicator demonstrates the quarterly proportions of specimens (first identified patientE. coli or coliform urine specimens, which were taken in a community setting) which have been tested for susceptibility to nitrofurantoin and found resistant (or intermediate) by laboratories (and recorded as originating from a community location) for patients in each ICB sub-location.Non-susceptibility by ICB sub-location has been graded to green (<25% of initialE.coliurine isolates), amber (25-49% isolates) and red for those where 50% or more have been identified as non-susceptible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
              "11 This indicator demonstrates the rolling average quarterly proportions ofgentamicin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility gentamicin by laboratories for patients in eachICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "12 This indicator demonstrates the rolling average quarterly proportions ofpiperacillin/tazobactam resistance in initial specimens (first identified patientE. coliblood specimens) which have been tested for susceptibility piperacillin/tazobactam by laboratories for patients in each Clinical Commissioning Group (CCG). A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by CCG has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by CCG in England. Those where less than 70% specimens have been tested for a particular CCG in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                              \n",
              "13 This indicator demonstrates the rolling average quarterly proportions of 3rd generation cephalosporin resistance in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to a 3rd generation cephalosporin (cefoxatime/ceftazidime/cefpodoxime/ceftriaxone) by laboratories for patients in each CICB sub-location. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-locationhas been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of 3rd generation cephalosporin resistance by ICB sub-location in England.Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).                                                                                                                                                                                                                                                                                                                                                                    \n",
              "14 This indicator demonstrates the rolling average quarterly proportions ofresistance to 3 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location. These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers. Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by CCG in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).               \n",
              "15 This indicator demonstrates the rolling average quarterly proportions of resistance to any 1 of the 5 key antimicrobials (gentamicin, ciprofloxacin,piperacillin/tazobactam, 3rd-generation cepholosporins or carbapenems) in initial specimens (first identified patientE. coli blood specimens) which have been tested for susceptibility to all 5 antimicrobials by laboratories for patients in eachICB sub-location.These indicators are provided to further public understanding of drug resistance and multi-drug resistance. They are useful to monitor the overall trends of antibiotic resistance in E. coli blood isolates and monitor the impact of antimicrobial stewardship. These indicators were not designed to inform clinical decision making.A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by ICB sub-location has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of multi-drug resistance by ICB sub-location in England. Those where less than 70% specimens have been tested for a particular ICB sub-location in at least one of the last 4 quarters a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).\n",
              "16 This indicator demonstrates the quarterly proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\\r\\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
              "17 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to a carbepenem in each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\\r\\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \n",
              "18 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\\r\\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "19 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust(mandatory surveillance) that have been tested for susceptibility to piperacillin/tazobactamin each NHS acute Trust by quarter, in line with national guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\\r\\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
              "20 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to 3rd generation cephalosporins in each NHS acute Trust by quarter, in line with the guidance. Testing by NHS acute Trust has been graded to green (100% of initialE.coliblood isolates), amber (70-99% isolates) and red for those where less than 70% have been tested.\\r\\nIf less than 70% of the acute Trust's mandatoryE. colibacteraemia reports have successfully linked to a laboratory reportthen a data quality issue is indicated in the presented value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \n",
              "21 A summary figure of gonorrhoea cultures tested for azithromycin susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes ceftriaxone and azithromycin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
              "22 A summary figure of gonorrhoea cultures tested for ceftriaxone susceptibility. Primary diagnostic laboratories should test all specimens for antimicrobial susceptibility to first-line antimicrobials, which includes azithromycin and ceftriaxone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \n",
              "23 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to gentamicin in each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of gentamicin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                                \n",
              "24 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to ciprofloxacin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of ciprofloxacin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's quarterly average mandatory E. coli bacteraemia reports have successfully linked to a laboratory report in then a data quality issue is indicated in the presented value.                                                                                                                                                                                                             \n",
              "25 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to piperacillin/tazobactam each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of piperacillin/tazobactam resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters)then a data quality issue is indicated in the presented value.                                                                                                                                                                                   \n",
              "26 This indicator demonstrates the proportion of patient linked mandatory and laboratory surveillance E. colibacteraemia episodes, presented by reporting acute Trust (mandatory surveillance)that have been tested for susceptibility to3rd generation cephalosporin each NHS acute Trust by quarter, in line with national guidance, and found resistant. A rolling quarterly average (across a 4 quarter period) is presented to comply with data protection regulations when dealing with low numbers.Resistance by acute Trust has been graded by colour in five groups, with the palest colours representing the lowest and the darkest the highest recorded proportions of3rd generation cephalosporin resistance by acute Trust in England.Those where less than 70% linked specimens have been tested in at least one of the last 4 quarters for a particular acute Trust a data quality indicator has been presented alongside the result (70% is the cut off used within the ESPAUR report 2014).If less than 70% of the acute Trust's mandatory E. coli bacteraemia reports have successfully linked to a laboratory report (average across 4 quarters) then a data quality issue is indicated in the presented value.                                                                                                                                                                          \n",
              "   Data source                                                                                                                                                               \n",
              "1  Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module\n",
              "2  Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.         \n",
              "3  Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "4  Routine Laboratory surveillance reports to Public Health England via the second generation surveillance system (SGSS); Antimicrobial testing data module.                 \n",
              "5  Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); antimicrobial testing data module.         \n",
              "6  Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "7  Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module\n",
              "8  Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module\n",
              "9  Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module\n",
              "10 Routine voluntary laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module\n",
              "11 Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "12 Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "13 Routine laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "14 Routine Laboratory surveillance reports to UKHSA via the second generation surveillance system (SGSS); Antimicrobial testing data module.                                 \n",
              "15 Routine Laboratory surveillance reports to the UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module.         \n",
              "16 Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    \n",
              "17 Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    \n",
              "18 Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    \n",
              "19 Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  \n",
              "20 Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  \n",
              "21 Public Health England                                                                                                                                                     \n",
              "22 Public Health England                                                                                                                                                     \n",
              "23 Routine voluntary laboratory surveillance reports to UK Health Security Agency’s via the second generation surveillance system (SGSS); Antimicrobial testing data module  \n",
              "24 Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    \n",
              "25 Routine voluntary laboratory surveillance reports to UK Health Security Agency's via the second generation surveillance system (SGSS); Antimicrobial testing data module  \n",
              "26 Routine voluntary laboratory surveillance reports to UK Health Security Agency via the second generation surveillance system (SGSS); Antimicrobial testing data module    \n",
              "   Indicator source\n",
              "1  NA              \n",
              "2  NA              \n",
              "3  NA              \n",
              "4  NA              \n",
              "5  NA              \n",
              "6  NA              \n",
              "7  NA              \n",
              "8  NA              \n",
              "9  NA              \n",
              "10 NA              \n",
              "11 NA              \n",
              "12 NA              \n",
              "13 NA              \n",
              "14 NA              \n",
              "15 NA              \n",
              "16 NA              \n",
              "17 NA              \n",
              "18 NA              \n",
              "19 NA              \n",
              "20 NA              \n",
              "21 NA              \n",
              "22 NA              \n",
              "23 NA              \n",
              "24 NA              \n",
              "25 NA              \n",
              "26 NA              \n",
              "   Methodology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
              "1  The percentage of antibiotic susceptibility tests in initial reportedE. coli positive patient blood specimens in England. Total number of carbapenem (meropenem/imipenem or ertapenem) susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                    \n",
              "2  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime) susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                        \n",
              "3  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                        \n",
              "4  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                                           \n",
              "5  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam susceptibility tests on initialE. colipositive blood specimens isdivided by the aggregated total of initialE. colipositive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                                              \n",
              "6  The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of ciprofloxacin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                         \n",
              "7  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.Total number of trimethoprim susceptibility tests on initial E. coli positive community urine specimens isdivided by the aggregated total of initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                       \n",
              "8  The percentage of non-susceptible (resistant or intermediate) test results in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England. Total number of trimethoprim non-susceptible test results on initial E. coli positive community urine specimens isdivided by the aggregated total of trimethoprim tested initial E. coli positive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Results are suppressed if susceptibility testing in that area over the time period (quarter) is <70%, or if the numerator or denominator are small numbers (<5). A zero value is still presented.\n",
              "9  The percentage of antibiotic susceptibility tests in initial reportedE. colipositive, or specimens reported as ‘coliform’ without further speciation, patient community urine specimens in England.\\r\\nTotal number of nitrofurantoin susceptibility tests on initialE. coli positive community urine specimens isdivided by the aggregated total of initialE. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\\r\\nData are suppressed if the numerator is <5 specimens or the denominator is <5 specimens.                                                                                                                                                        \n",
              "10 The percentage of antibiotic non-susceptibility in initial reportedE. coli, or specimens reported as ‘coliform’ without further speciation,positive patient community urine specimens in England. Total number of nitrofurantoin non-susceptible community initial E. colipositive community urine specimens isdivided by the aggregated total of nitrofurantoin tested initial E. colipositive community urine specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.Data are suppressed if the numerator is <5 specimens, the denominator is <5 specimens or the proportion tested in the area is <70%.                                                                                             \n",
              "11 The quarterly average percentage of resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of gentamicin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                               \n",
              "12 The quarterly average percentage ofresistantantibiotic test results in initial reportedE. colipositive patient blood specimens in England. Total number of piperacillin/tazobactam resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactam susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                      \n",
              "13 The quarterly average percentage of resistantantibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of 3rd-generation cephalosporin resistant test resultson initialE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd-generation cephalosporin susceptibility testson initialE. colipositive blood specimens across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                            \n",
              "14 The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England. Total number of test resultson initialE. colipositive blood specimens resistantto 3 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                            \n",
              "15 The quarterly average percentage of combination resistant antibiotictest results in initial reportedE. colipositive patient blood specimens in England.Total number of test resultson initialE. colipositive blood specimens resistantto any 1 of the 5 key strategy antimicrobialsfor the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of susceptibility testson initialE. colipositive blood specimens for all 5 of the key antimicrobials across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                          \n",
              "16 The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. For each quarter: Total number of gentamicin susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                           \n",
              "17 The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of carbapenem susceptibility tests on initial E. coli positive blood specimens isdivided by the aggregated total of linked initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                          \n",
              "18 The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin susceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                                 \n",
              "19 The percentage of antibiotic susceptibility tests in a patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactamsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.                                                                                                                                                                                                                                                                                                        \n",
              "20 The percentage of antibiotic susceptibility tests in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Quarterly total number of 3rd generation cephalosporinsusceptibility tests on linked initial E. coli positive blood specimens isdivided by the aggregated total of initial E. coli positive blood specimens reported at the specified geography. Results are multiplied by 100 to be viewed as a percentage.\\r\\nThe 3rd generation cephalosporins considered in this indicator are: cefotaxime, ceftazidime, cefpodoxime and/or ceftriaxone. Tests to one or multiple are taken into account.                                                                                                          \n",
              "21 Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \n",
              "22 Percentage. The numerator is divided by the denominator and multiplied by 100.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \n",
              "23 Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of gentamicin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofgentamicin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                           \n",
              "24 Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of ciprofloxacin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofciprofloxacin susceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                                     \n",
              "25 Thequarterly averagepercentage ofresistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of piperacillin/tazobactam resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number ofpiperacillin/tazobactamsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                                   \n",
              "26 Thequarterly averagepercentage of resistantantibiotictest results in patient linkedE. coli positive blood specimens recorded by an acute Trust setting in England. Total number of3rd generation cephalosporin resistant test resultson linkedE. colipositive blood specimens for the most recent 4 quarters is aggregated and divided by 4; creating the average quarterly value across the last year. This value is divided by the average quarterly value for the number of3rd generation cephalosporinsusceptibility testson linkedE. colipositive blood specimens across the last yearat the specified geography.Results are multiplied by 100 to be viewed as a percentage.                                                                         \n",
              "   Standard population/values\n",
              "1  NA                        \n",
              "2  NA                        \n",
              "3  NA                        \n",
              "4  NA                        \n",
              "5  NA                        \n",
              "6  NA                        \n",
              "7  NA                        \n",
              "8  NA                        \n",
              "9  NA                        \n",
              "10 NA                        \n",
              "11 NA                        \n",
              "12 NA                        \n",
              "13 NA                        \n",
              "14 NA                        \n",
              "15 NA                        \n",
              "16 NA                        \n",
              "17 NA                        \n",
              "18 NA                        \n",
              "19 NA                        \n",
              "20 NA                        \n",
              "21 NA                        \n",
              "22 NA                        \n",
              "23 NA                        \n",
              "24 NA                        \n",
              "25 NA                        \n",
              "26 NA                        \n",
              "   Confidence interval details                         \n",
              "1  No confidence intervals generated for this indicator\n",
              "2  No confidence intervals generated for this indicator\n",
              "3  NA                                                  \n",
              "4  NA                                                  \n",
              "5  NA                                                  \n",
              "6  NA                                                  \n",
              "7  No confidence intervals generated for this indicator\n",
              "8  No confidence intervals generated for this indicator\n",
              "9  No confidence intervals generated for this indicator\n",
              "10 No confidence intervals generated for this indicator\n",
              "11 NA                                                  \n",
              "12 NA                                                  \n",
              "13 NA                                                  \n",
              "14 NA                                                  \n",
              "15 NA                                                  \n",
              "16 No confidence intervals generated for this indicator\n",
              "17 No confidence intervals generated for this indicator\n",
              "18 No confidence intervals generated for this indicator\n",
              "19 No confidence intervals generated for this indicator\n",
              "20 No confidence intervals generated for this indicator\n",
              "21 NA                                                  \n",
              "22 NA                                                  \n",
              "23 No confidence intervals generated for this indicator\n",
              "24 No confidence intervals generated for this indicator\n",
              "25 No confidence intervals generated for this indicator\n",
              "26 No confidence intervals generated for this indicator\n",
              "   Source of numerator                                                                                                                                                                                                                                                                                                                                                 \n",
              "1  Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                            \n",
              "2  Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "3  Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "4  Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "5  Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "6  Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "7  Voluntary laboratory reports ofEscherichia coli(E. coli) or coliform positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                    \n",
              "8  Voluntary laboratory reports ofEscherichia coli(E. coli; or coliform) positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                            \n",
              "9  Voluntary laboratory reports ofEscherichia coli(E. coli) positive GP urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                                                \n",
              "10 Voluntary laboratory reports ofEscherichia coli(E. coli)or coliform positive community urine specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module                                                                              \n",
              "11 Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "12 Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "13 Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "14 Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "15 Laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS)                                                                                                                                                   \n",
              "16 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "17 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "18 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "19 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "20 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "21 Azithromycin susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                     \n",
              "22 Ceftriaxone susceptibility testing data are sourced from SGSS.                                                                                                                                                                                                                                                                                                      \n",
              "23 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "24 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "25 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "26 Voluntary laboratory reports ofEscherichia coli(E. coli) blood specimens made by English laboratories to the routine laboratory surveillance scheme and extracted from UKHSA's Second Generation Surveillance System (SGSS) antimicrobial testing module which have been successfully linked (by patient) to a mandatory surveillance report of E. coli bacteraemia.\n",
              "   ⋯ Indicator Content Specific rationale Simple Name Simple Definition\n",
              "1  ⋯ NA                NA                 NA          NA               \n",
              "2  ⋯ NA                NA                 NA          NA               \n",
              "3  ⋯ NA                NA                 NA          NA               \n",
              "4  ⋯ NA                NA                 NA          NA               \n",
              "5  ⋯ NA                NA                 NA          NA               \n",
              "6  ⋯ NA                NA                 NA          NA               \n",
              "7  ⋯ NA                NA                 NA          NA               \n",
              "8  ⋯ NA                NA                 NA          NA               \n",
              "9  ⋯ NA                NA                 NA          NA               \n",
              "10 ⋯ NA                NA                 NA          NA               \n",
              "11 ⋯ NA                NA                 NA          NA               \n",
              "12 ⋯ NA                NA                 NA          NA               \n",
              "13 ⋯ NA                NA                 NA          NA               \n",
              "14 ⋯ NA                NA                 NA          NA               \n",
              "15 ⋯ NA                NA                 NA          NA               \n",
              "16 ⋯ NA                NA                 NA          NA               \n",
              "17 ⋯ NA                NA                 NA          NA               \n",
              "18 ⋯ NA                NA                 NA          NA               \n",
              "19 ⋯ NA                NA                 NA          NA               \n",
              "20 ⋯ NA                NA                 NA          NA               \n",
              "21 ⋯ NA                NA                 NA          NA               \n",
              "22 ⋯ NA                NA                 NA          NA               \n",
              "23 ⋯ NA                NA                 NA          NA               \n",
              "24 ⋯ NA                NA                 NA          NA               \n",
              "25 ⋯ NA                NA                 NA          NA               \n",
              "26 ⋯ NA                NA                 NA          NA               \n",
              "   Impact of COVID-19 Unit Value type Year type Polarity          Date updated\n",
              "1  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "2  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "3  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "4  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "5  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "6  NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "7  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "8  NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "9  NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "10 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "11 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "12 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "13 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "14 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "15 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "16 NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "17 NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "18 NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "19 NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "20 NA                 %    Proportion Calendar  Not applicable    14/03/2024  \n",
              "21 NA                 %    Proportion Calendar  Not applicable    27/02/2023  \n",
              "22 NA                 %    Proportion Calendar  Not applicable    28/02/2023  \n",
              "23 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "24 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "25 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  \n",
              "26 NA                 %    Proportion Calendar  RAG - Low is good 14/03/2024  "
            ]
          },
          "metadata": {}
        }
      ]
    }
  ]
}